

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Covidogram as a simple tool for predicting severe course of COVID-19: population based study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-045442
Article Type:	Original research
Date Submitted by the Author:	01-Oct-2020
Complete List of Authors:	Jarkovský, Jiří; Masaryk University Institute of Biostatistics and Analyses; Institute of Health Information and Statistics of the Czech Republic Benešová, Klára; Institute of Health Information and Statistics of the Czech Republic; Institute of Health Information and Statistics of the Czech Republic Cerny, Vladimir; Masaryk Hospital in Usti nad Labem, Anesth. and ICU; Dalhousie University, Cerny Vladimir Razova, Jarmila; Ministry of Health of the Czech Republic Kala, petr; Masaryk University; University Hospital Brno Dolina, Jiri; University Hospital Brno; Masaryk University Majek, Ondrej; Institute of Health Information and Statistics of the Czech Republic; Masaryk University Institute of Biostatistics and Analyses Sebestova, Silvie; Institute of Health Information and Statistics of the Czech Republic Bezdekova, Monika; Institute of Health Information and Statistics of the Czech Republic Melicharova, Hana; Institute of Health Information and Statistics of the Czech Republic Snajdrova, Lenka; Institute of Health Information and Statistics of the Czech Republic; Masaryk University Institute of Biostatistics and Analyses Dusek, Ladislav; Institute of Health Information and Statistics of the Czech Republic; Masaryk University Institute of Biostatistics and Analyses Parenica, Jiri; University Hospital Brno, Internal and Cardiology Department; Masaryk University
Keywords:	COVID-19, Gastroduodenal disease < GASTROENTEROLOGY, Organisation of health services < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Covidogram as a simple tool for predicting severe course of COVID-19:**  
4  
5  
6 **population based study**  
7  
8  
9

10  
11 Jiri Jarkovsky<sup>1,2</sup>, Klara Benesova<sup>1,2</sup>, Vladimir Cerny<sup>3,4</sup>, Jarmila Razova<sup>5</sup>, Petr  
12  
13 Kala<sup>6,7</sup>, Jiri Dolina<sup>7,8</sup>, Ondrej Majek<sup>1,2</sup>, Silvie Sebestova<sup>1</sup>, Monika Bezdekova<sup>1</sup>,  
14  
15 Hana Melicharova<sup>1</sup>, Lenka Snajdrova<sup>1,2</sup>, Ladislav Dusek<sup>1,2</sup> and Jiri Parenica<sup>1,6,7</sup>  
16  
17

18  
19  
20 <sup>1</sup> Institute of Health Information and Statistics of the Czech Republic, Prague,  
21  
22  
23 Czech Republic  
24

25  
26 <sup>2</sup> Institute of Biostatistics and Analysis, Faculty of Medicine, Masaryk University,  
27  
28  
29 Brno, Czech Republic  
30

31  
32 <sup>3</sup> Department of Anaesthesiology, Perioperative Medicine and Intensive Care,  
33  
34  
35 J.E. Purkinje University, Masaryk Hospital, Usti nad Labem, Czech Republic  
36

37  
38 <sup>4</sup>Department of Anesthesia, Pain Management and Perioperative Medicine,  
39  
40  
41 Dalhousie University, Halifax, Canada  
42

43  
44 <sup>5</sup> Ministry of Health, Czech Republic  
45

46  
47 <sup>6</sup> Internal and Cardiology Department, University Hospital Brno, Czech Republic  
48

49  
50 <sup>7</sup> Faculty of Medicine, Masaryk University, Brno, Czech Republic  
51

52  
53  
54  
55 <sup>8</sup> Gastroenterology and Internal Department, University Hospital Brno, Czech  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

**Key words:** Covid-19; severe course; prognostic score; proton-pump inhibitors

1  
2  
3  
4  
5  
6 **A funding statement** This research received no specific grant from any funding  
7  
8 agency in the public, commercial or not-for-profit sectors  
9

10  
11 **A competing interests statement** All authors have disclosed that they do not  
12  
13 have any conflicts of interest (no support from any organisation for the  
14  
15 submitted work; no financial relationships with any organisations that might  
16  
17 have an interest in the submitted work; no other relationships or activities that  
18  
19 could appear to have influenced the submitted work)  
20  
21  
22

23  
24 **Word count** 2211 (without abstract, tables, references)  
25

26  
27 **Contributors** JJ, LD, VC and JR designed the study and wrote the research plan.  
28  
29 OM, SS, MB, HM extracted the data used for the study from the databases. JJ  
30  
31 and KB undertook statistical analysis with feedback from LD. JP, JJ, PK, JD  
32  
33 interpreted the results and wrote the first draft of the manuscript with critical  
34  
35 comments and revision from VC, LD and LS.  
36  
37  
38  
39

40  
41 **Patient and public involvement** Patients and/or the public were not involved in  
42  
43 the design, or conduct, or reporting, or dissemination plans of this research.  
44  
45  
46  
47

48  
49 **Patient consent for publication** The analysis was done on data from the National  
50  
51 Health Information System (NHIS), which was supplemented with data from the  
52  
53 Information System of Infectious Diseases (ISID). Data in the ISID are collected in  
54  
55 compliance with Act No. 258/2000 Coll. on Protection of Public Health, data in  
56  
57  
58  
59  
60

1  
2  
3 the NHIS are collected – and interconnected with data from ISID – in accordance  
4  
5  
6 with Act No. 372/2011 Coll., on Health Services and Conditions of Their Provision.  
7

8  
9 Due to this legal mandate, the retrospective analyses did not require either  
10  
11 approval by an ethics committee or informed consents from participants.  
12  
13

14 **Data availability statement** The anonymized data available upon reasonable  
15  
16 request. The data are deidentified participant data, and available from the first  
17  
18 author JJ ([jarkovsky@uzis.cz](mailto:jarkovsky@uzis.cz)). The reuse of the data subset is permitted only for  
19  
20 revalidation of the results.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Corresponding author:**  
4

5  
6 Jiri Parenica, MD, MSc, PhD, Professor,  
7

8  
9 Internal and Cardiology Department, University Hospital Brno,  
10

11  
12 Jihlavská 20, 625 00 Brno, Czech Republic  
13

14  
15 e-mail: [jiri.parenica@atlas.cz](mailto:jiri.parenica@atlas.cz)  
16

17  
18 Telephone: +420 53223 2654; Fax: +420 532232907  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

**Objectives** COVID-19 might either be entirely asymptomatic or manifest itself with a large variability of disease severity. It is beneficial to identify early patients with a high risk of severe course. The aim of the analysis was to determine factors for the development of the severe acute respiratory infection.

**Design** A population based study.

**Setting** Czech Republic.

**Participants** The first 7,455 consecutive COVID-19 patients who were identified by PCR testing from 1 March 2020 to 17 May 2020.

**Interventions** None

**Primary outcome** Severe course of Covid-19.

**Result** Of a total 6.2% of patients developed a severe course of COVID-19. Age, male sex, chronic kidney disease, chronic obstructive pulmonary disease, recent history of cancer, chronic heart failure, acid-related disorders and diabetes mellitus were found to be independent negative prognostic factors. (AUC was 0.893). The results were visualised by risk heat maps and we called this diagram a “covidogram”. Acid-related disorders, predominantly treated with proton-pump inhibitors, might represent a negative prognostic factor.



1  
2  
3 **Conclusion** We developed a very simple prediction model called “covidogram”,  
4  
5  
6 which is based on elementary independent variables (age, male sex and the  
7  
8  
9 presence of several chronic diseases) and represents a tool that makes it  
10  
11  
12 possible to identify – with a high reliability – patients who are at risk of a severe  
13  
14  
15 course of COVID-19. Obtained results open clinically relevant question about  
16  
17  
18 the role of acid-related disorders treated by proton pump inhibitors as  
19  
20  
21 predictor for severe course of COVID-19.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Strengths and limitations of the study

- Age, male sex, chronic kidney disease, chronic obstructive pulmonary disease, recent history of cancer, chronic heart failure, acid-related disorders and diabetes mellitus represent independent negative prognostic factors of severe course of COVID-19 in consecutive patients.
- The proposed prediction model “covidogram” is a simple tool that makes it possible to identify – with a high reliability (AUC 0.893) – patients who are at risk of a severe course of COVID-19.
- Acid-related disorders treated with proton-pump inhibitors might be predictor of a severe course of the disease.
- Due to the retrospective nature of this study, which is based on data of administrative registries, results of laboratory, clinical and X-ray examinations were not available. Conclusions regarding the influence of comorbidities and the consumption of medicinal products should be interpreted with caution and will require further validation.

## Introduction

The coronavirus disease 2019 (COVID-19) is caused by betacoronavirus SARS-CoV-2, which enters human cells via the membrane-bound angiotensin-converting enzyme 2 (ACE2)[1]. The presence of infection might be entirely asymptomatic[2], or manifest itself with a large variability of disease severity, a number of unspecific clinical symptoms (fever, fatigue, myalgia) and various degrees of organ dysfunction. Most frequently, the disease affects the respiratory system (manifested as dry cough, dyspnoea, haemoptysis, pneumonia or ARDS) and the cardiovascular system (presented as myocardial injury or myocarditis, ventricular arrhythmias, haemodynamic instability or deep vein thrombosis), while other organ systems (such as the central nervous, gastrointestinal system or kidneys) are affected less frequently. In a number of patients, there is a risk of multiple organ failure, ultimately leading to death[3–7]. The management of COVID-19 patients depends on the disease severity: patients with a mild course of the disease can be treated in their home environment[8]. However, the clinical course might progress over time[5], and it is therefore clinically relevant to identify patients with a high risk of severe course of the disease as early as possible [9]. It was repeatedly demonstrated that older age, chronic obstructive pulmonary disease, diabetes mellitus,

1  
2  
3 chronic renal disease and cardiovascular disease are related to a high-risk  
4  
5  
6 course of the disease[5,10,11].  
7

8  
9 In the Czech Republic, a prospective population-based and centralised  
10  
11 collection of data on COVID-19 patients was developed at the beginning of the  
12  
13 pandemic, with a possibility to interconnect these data with those recorded in  
14  
15 other population-based registries of the National Health Information System  
16  
17 (NHIS), and thus to obtain information on each patient's history and  
18  
19 management.  
20  
21  
22  
23  
24  
25

26 The aim of this study was to determine factors for the development of  
27  
28 the severe acute respiratory infection, defined by the necessity of intensive  
29  
30 care being provided in the Intensive care units (ICU), that include mechanical  
31  
32 ventilation, extracorporeal membrane oxygenation (ECMO) support and/or  
33  
34 death.  
35  
36  
37  
38  
39  
40  
41  
42

## 43 **Methods**

### 44 ***Population of patients***

45  
46 The analysis is based on data from a population-based registry containing  
47  
48 records of all consecutive COVID-19 patients in the Czech Republic who were  
49  
50 identified by PCR testing and validated by the National Institute of Public  
51  
52 Health.  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 The monitored cohort consisted of patients who were recorded in the  
4  
5  
6 National Information System of Infectious Diseases (ISID) between 1 March  
7  
8  
9 2020 and 17 May 2020.

10  
11 As of 17 May 2020, a total of 356,515 tests were performed in the Czech  
12  
13  
14 Republic, and the diagnosis of COVID-19 was confirmed in 8,475 cases. Of the  
15  
16  
17 confirmed COVID-19 cases, 464 patients with still unknown history in the  
18  
19  
20 National Health Information System (NHIS) or the patients being foreign  
21  
22  
23 nationals with unknown medical history – were excluded from the analysis, and  
24  
25  
26 further 556 patients with a follow-up period shorter than 14 days. were  
27  
28  
29 excluded as well. 90% of events occur within 14 days (Figure S1). Analysis  
30  
31  
32 without censoring and with a fixed follow-up length was chosen with the  
33  
34  
35 objective to simplify visualisation and interpretation of results of the analysis  
36  
37  
38 for its practical application. On top of that, characteristics of the cohort  
39  
40  
41 diagnosed with COVID-19 were compared to those of the population of the  
42  
43  
44 Czech Republic (10.6 million).

### 45 **Diagnosis**

46  
47  
48 The diagnosis of COVID-19 was based on the detection of SARS-CoV-2 by  
49  
50  
51 real-time reverse transcription polymerase chain reaction (RT-PCR). At first, the  
52  
53  
54 analyses were performed in the National Reference Laboratory of the National  
55  
56  
57  
58  
59  
60

1  
2  
3 Institute of Public Health (NIPH); other certified laboratories were later  
4  
5  
6 appointed to carry out PCR testing as well.  
7

### 8 ***Systematic collection of data***

9  
10 The analysis was done on data from the National Health Information  
11  
12 System (NHIS), which was supplemented with data from the Information  
13  
14 System of Infectious Diseases (ISID). Data in the ISID are collected in  
15  
16 compliance with Act No. 258/2000 Coll. on Protection of Public Health,  
17  
18 whereas data in the NHIS are collected – and interconnected with data from  
19  
20 ISID – in accordance with Act No. 372/2011 Coll., on Health Services and  
21  
22 Conditions of Their Provision. Due to this legal mandate, the retrospective  
23  
24 analyses did not require either approval by an ethics committee or informed  
25  
26 consents from participants; moreover, it is a population-based analysis of all  
27  
28 COVID-19 cases in the Czech Republic.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

40 The latest data on COVID-19 patients, the severity of their condition as well as  
41  
42 the necessity of hospitalisation in an ICU, including the use of mechanical  
43  
44 ventilation or ECMO, together with information on death, have been entered  
45  
46 into the ISID in real time. Apart from that, data on COVID-19 patients have  
47  
48 been enriched with information on their comorbidities: this information is  
49  
50 available in the National Register of Reimbursed Health Services (NRHZS),  
51  
52 which contains data on all healthcare reported within the public health  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 insurance system (accounting for almost 100% of healthcare provided in the  
4  
5  
6 Czech Republic). Comorbidities are determined from combinations of reported  
7  
8  
9 diagnoses (ICD-10), ATC codes of drugs, and procedures defined in code lists  
10  
11  
12 used by Czech health insurance companies. Only diseases and conditions with a  
13  
14  
15 higher prevalence in the population or those identified in literature[5,7,12,13]  
16  
17  
18 as potential predictors of a severe course of COVID-19 were evaluated, with the  
19  
20  
21 aim to assess their potential influence on the resulting model.  
22

### 23 ***Statistical analysis***

24  
25  
26 Standard descriptive statistics were used to describe the data:  
27  
28  
29 categorical variables were described by absolute and relative frequencies,  
30  
31  
32 whereas continuous variables were described by means and standard  
33  
34  
35 deviations. The Fisher's exact test (for categorical variables) and Mann–  
36  
37  
38 Whitney U test (for continuous variables) were used to compare characteristics  
39  
40  
41 between groups depending on the monitored endpoint, unless stated  
42  
43  
44 otherwise. The predictive power of patient characteristics with regard to the  
45  
46  
47 analysed endpoint was evaluated by univariate and multivariate logistic  
48  
49  
50 regression and described by odds ratios, their 95% confidence intervals and  
51  
52  
53 statistical significance; a backward stepwise algorithm was used to choose the  
54  
55  
56 optimum model, and a ROC analysis was employed to evaluate the overall  
57  
58  
59 predictive power of the model. The results of the model were expressed by a  
60

1  
2  
3 nomogram in the form of a risk heat map taking account of the patients' age,  
4  
5 sex and comorbidities. A 10-fold cross-validation was performed to reduce the  
6  
7 likelihood of model overfitting. The analysis was computed using the Vertica  
8  
9 database and a MS SQL Server for data pre-processing and SPSS 25.0.0.1. for  
10  
11 the statistical analysis of data. The level of statistical significance was set at  
12  
13  
14  
15  
16  
17  $\alpha=0.05$  for all analyses.  
18  
19  
20  
21  
22

## 23 **Results**

24  
25  
26 Of the total of 7,455 evaluated patients, 1,182 (15.9%) were hospitalised,  
27  
28 465 of them (6.2%) developed a severe course of the disease (i.e. reached the  
29  
30 primary endpoint), 174 patients (2.3%) required mechanical ventilation, 11  
31  
32 patients (0.1%) were provided ECMO, and 287 patients (3.8%) died. Patients  
33  
34 with the monitored endpoint were older ( $74.8 \pm 13.4$  vs  $45.4 \pm 20.2$  years),  
35  
36 more frequently of male sex and suffered at least one of all monitored  
37  
38 comorbidities (Table 1,  $p < 0.001$  for all parameters). Older age was  
39  
40 determined by the multivariate logistic regression analysis to be the most  
41  
42 significant predictor: the risk of a severe course of the disease increases  
43  
44 progressively from the age of 40 years onwards (Table 2). Male sex, chronic  
45  
46 kidney disease, chronic obstructive pulmonary disease, recent history of cancer  
47  
48 (in the last five years), chronic heart failure, acid-related disorders and diabetes  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 mellitus were other significant predictors; the latter six conditions are  
4  
5  
6 hereinafter referred to as **prognostically significant comorbidities** (Table 2).  
7

8  
9 The overall predictive power of the model, evaluated by the C-statistic and  
10  
11 expressed by the AUC, was 0.893 (95% CI: 0.880–0.907; sensitivity 85.8% and  
12  
13 specificity 80.3%). After performing the 10-fold cross-validation to validate the  
14  
15 results, the average AUC of 0.891 (in the range 0.856–0.943) was obtained. For  
16  
17 the purpose of an easier interpretation in clinical practice, a simplified version  
18  
19 of the model was developed, taking into consideration the number of  
20  
21 prognostically significant comorbidities obtained from the previous model  
22  
23 (Table S1). The results were visualised by risk heat maps for men and women  
24  
25 separately (Figure 1), and we called this diagram a “**covidogram**”. The diagram  
26  
27 shows how the risk increases progressively with age and with the number of  
28  
29 prognostically significant comorbidities.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

40 It is obvious from the comparison of basic patient characteristics (Table 1) and  
41  
42 the results of the multivariate analysis (Table 2) that although a number of  
43  
44 conditions occur more frequently in the group of patients with a severe course  
45  
46 of the disease, not all of them are independent predictors (coronary artery  
47  
48 disease, history of stroke, atrial fibrillation, hypertension or treatment by ACEIs  
49  
50 and ARBs).  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 The comparison of characteristics of patients with confirmed COVID-19  
4  
5  
6 to those of the entire population of the Czech Republic showed that COVID-19  
7  
8  
9 patients are slightly older and have the monitored comorbidities slightly more  
10  
11 frequently. (Table S2).  
12  
13  
14  
15  
16

## 17 Discussion

### 18 19 20 *New findings about COVID-19*

21  
22  
23 We have described prognostically significant factors that increase the risk  
24  
25 of a severe course of COVID-19 in consecutive patients with positive COVID-19  
26  
27 PCR test. Age is the most significant factor, and the risk increases progressively  
28  
29 from the age of 40 years onwards. To our knowledge, this is the first study to  
30  
31 suggest that acid-related disorders treated by proton pump inhibitors might be  
32  
33 independent risk predictors as well. By contrast, not all cardiovascular diseases  
34  
35 (such as uncomplicated hypertension) increase the risk of a severe course of  
36  
37 COVID-19. We have developed a simple tool called “covidogram” for an early  
38  
39 identification of risk of a severe course of the disease. This model has a very  
40  
41 good predictive power (AUC 0.893).  
42  
43  
44  
45  
46  
47  
48  
49  
50

51 The “covidogram” was designed as a model to assess the risk of  
52  
53 unfavourable development of the patient’s condition based on his/her history  
54  
55 of chronic disease, and can serve as a tool to estimate the number of severe  
56  
57  
58  
59  
60

1  
2  
3 cases of COVID-19 in a population. When assessing the risk for an individual  
4  
5 patient in clinical practice, it is certainly necessary to take into consideration  
6  
7 also other pieces of information on the current condition of that patient  
8  
9  
10 (respiratory rate, peripheral oxygen saturation, level of consciousness, urea  
11  
12 level, C reactive protein[14], procalcitonin, aspartate aminotransferase[13],  
13  
14 high temperature[12], elevation of cardiac markers, lung infiltrates >50%[7]) as  
15  
16 well as obesity, which can also increase the risk of a severe course of COVID-19  
17  
18 [15].  
19  
20  
21  
22  
23  
24  
25

### 26 ***Acid-related disorders***

27  
28 Surprisingly, our analysis revealed that the presence of acid-related  
29  
30 disorders might be an independent predictor of a severe course of COVID-19.  
31  
32 Patients were predominantly treated with proton-pump inhibitors (1,175  
33  
34 patients in total, out of which 706 were treated with omeprazole and 402 with  
35  
36 pantoprazole as the two most frequently used drugs); only a small proportion  
37  
38 of them were treated with H<sub>2</sub>-receptor antagonists (30 patients). The main  
39  
40 indications for treatment with these drugs generally involve gastro-  
41  
42 oesophageal reflux disease, functional dyspepsia, gastric and duodenal ulcers,  
43  
44 gastric acid hypersecretory states as well as gastroprotection in patients using  
45  
46 non-steroidal anti-inflammatory drugs or dual antiplatelet therapy. The effect  
47  
48 of inhibition of hydrochloric acid secretion is followed by an increase in the  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 intragastric pH (to a value above 2–4), which might hypothetically decrease the  
4  
5  
6 physiological bactericidal/virucidal effect of gastric acid and decrease the  
7  
8  
9 activity of lysosomal enzymes. Published data showed that long-term use of  
10  
11  
12 proton-pump inhibitors could slightly increase the risk of pneumonia[16,17]  
13  
14  
15 and enteric infections[18].

16  
17 Our comparison of patients with and without acid-related disorders (Table S3)  
18  
19  
20 showed that patients with these disorders are markedly older and have  
21  
22  
23 prognostically significant comorbidities more frequently. Our analysis cannot  
24  
25  
26 determine whether there is any causal relationship between the presence of  
27  
28  
29 acid-related disorders and a severe course of COVID-19 or whether it is just a  
30  
31  
32 coincidence. At the same time, it must be stressed out that the vast majority of  
33  
34  
35 patients were treated with proton-pump inhibitors, not with H<sub>2</sub>-receptor  
36  
37  
38 agonists. Recently, Almario et al. demonstrated association between using  
39  
40  
41 proton pump inhibitors and odds of a positive COVID-19 test [19]. Similar trend  
42  
43  
44 was reported by Tarlow [20].

### 45 46 **Strengths and limitations**

47  
48  
49 This study is based on a fully integrated national health information  
50  
51  
52 system covering the entire population of a country – which proposed a  
53  
54  
55 prediction model estimating individually-based risk of a severe course of  
56  
57  
58 COVID-19. Because this model uses data readily available in health and  
59  
60

1  
2  
3 administrative registries, it can be easily used for the prediction of intensive  
4  
5  
6 care use in the context of decision-making at the national level.  
7

8  
9 On the other hand, our analysis has a number of limitations. Results of  
10  
11 laboratory, clinical and X-ray examinations performed at the time of patient  
12  
13 admission to hospitals were not available, and these very important pieces of  
14  
15 information could therefore not be analysed; instead, our analysis is based on  
16  
17 administrative data, with the exception of endpoints. Furthermore, analytical  
18  
19 processing of a cohort of patients cannot capture the risk of less frequent  
20  
21 conditions that might increase the risk of a severe course of COVID-19 (e.g.  
22  
23 patients with immunodeficiencies, those after organ transplantation, or those  
24  
25 undergoing immunosuppressive therapy or biological therapy). Due to the  
26  
27 retrospective nature of this study, which is based on data of administrative  
28  
29 registries and is focused on the development of a prediction model, any  
30  
31 conclusions regarding the influence of comorbidities and the consumption of  
32  
33 medicinal products should be interpreted with caution and will require further  
34  
35 validation.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

## 51 **Conclusion**

52  
53  
54 The proposed prediction model “covidogram” is based on elementary  
55  
56 independent variables (age, male sex and the presence of chronic disease) and  
57  
58  
59  
60

1  
2  
3 represents a simple tool that makes it possible to identify – with a high  
4  
5  
6 reliability (AUC 0.893) – patients who are at risk of a severe course of COVID-  
7  
8  
9 19.

10  
11 Finally, the analysis has shown, for the first time, that acid-related disorders  
12  
13  
14 treated with proton-pump inhibitors might also be predictor of a severe course  
15  
16  
17 of the disease.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## References

- 1 Hoffmann M, Kleine-Weber H, Schroeder S, *et al.* SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* 2020;**181**:271-280.e8. doi:10.1016/j.cell.2020.02.052
- 2 Sutton D, Fuchs K, D'Alton M, *et al.* Universal Screening for SARS-CoV-2 in Women Admitted for Delivery. *N Engl J Med* Published Online First: 13 April 2020. doi:10.1056/NEJMc2009316
- 3 Giacomelli A, Pezzati L, Conti F, *et al.* Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study. *Clin Infect Dis Off Publ Infect Dis Soc Am* Published Online First: 26 March 2020. doi:10.1093/cid/ciaa330
- 4 Han C, Duan C, Zhang S, *et al.* Digestive Symptoms in COVID-19 Patients With Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes. *Am J Gastroenterol* Published Online First: 15 April 2020. doi:10.14309/ajg.0000000000000664
- 5 Huang C, Wang Y, Li X, *et al.* Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet Lond Engl* 2020;**395**:497–506. doi:10.1016/S0140-6736(20)30183-5
- 6 Kim I-C, Kim JY, Kim HA, *et al.* COVID-19-related myocarditis in a 21-year-old female patient. *Eur Heart J* Published Online First: 13 April 2020. doi:10.1093/eurheartj/ehaa288
- 7 Wang D, Hu B, Hu C, *et al.* Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. *JAMA* 2020;**323**:1061–9. doi:10.1001/jama.2020.1585
- 8 Gandhi RT, Lynch JB, Rio C del. Mild or Moderate Covid-19. *N Engl J Med* Published Online First: 24 April 2020. doi:10.1056/NEJMc2009249
- 9 Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. *N Engl J Med* 2020;**0**:null. doi:10.1056/NEJMc2009575

- 10 Mehra MR, Desai SS, Kuy S, *et al.* Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. *N Engl J Med* Published Online First: 1 May 2020. doi:10.1056/NEJMoa2007621
- 11 Wang T, Tang C, Chen R, *et al.* Clinical Features of Coronavirus Disease 2019 Patients With Mechanical Ventilation: A Nationwide Study in China. *Crit Care Med* 2020;**Online First**. doi:10.1097/CCM.0000000000004473
- 12 Wu C, Chen X, Cai Y, *et al.* Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med* Published Online First: 13 March 2020. doi:10.1001/jamainternmed.2020.0994
- 13 Chen R, Liang W, Jiang M, *et al.* Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China. *Chest* Published Online First: 15 April 2020. doi:10.1016/j.chest.2020.04.010
- 14 Knight SR, Ho A, Pius R, *et al.* Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. *BMJ* 2020;**370**. doi:10.1136/bmj.m3339
- 15 Malik P, Patel U, Patel K, *et al.* Obesity a predictor of outcomes of COVID-19 hospitalized patients- A systematic Review and Meta-Analysis. *J Med Virol* Published Online First: 25 September 2020. doi:10.1002/jmv.26555
- 16 Eom C-S, Jeon CY, Lim J-W, *et al.* Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. *CMAJ Can Med Assoc J J Assoc Medicale Can* 2011;**183**:310–9. doi:10.1503/cmaj.092129
- 17 Zirk-Sadowski J, Masoli JA, Delgado J, *et al.* Proton-Pump Inhibitors and Long-Term Risk of Community-Acquired Pneumonia in Older Adults. *J Am Geriatr Soc* 2018;**66**:1332–8. doi:10.1111/jgs.15385
- 18 Moayyedi P, Eikelboom JW, Bosch J, *et al.* Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. *Gastroenterology* 2019;**157**:682-691.e2. doi:10.1053/j.gastro.2019.05.056
- 19 Almario CV, Chey WD, Spiegel BMR. Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors. *Am J Gastroenterol* Published Online First: 25 August 2020. doi:10.14309/ajg.0000000000000798



1  
2  
3 20 Tarlow B, Gubatan J, Khan MA, *et al.* Are Proton Pump Inhibitors  
4 Contributing to SARS-COV-2 Infection? *Off J Am Coll Gastroenterol ACG*  
5 2020; **Publish Ahead of Print.** doi:10.14309/ajg.0000000000000933  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1  
2  
3 **Figure legend**  
4

5  
6 Figure 1. COVIDOGRAM – predicted probability of severe course of Covid-19 for  
7  
8 men and women – visualization of simplified multivariate logistic regression  
9  
10 model (for more details, see Supplemental Table 1)  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

**Table 1.** Characteristics of COVID-19 patients according to endpoint

	<b>With severe course</b> <b>N = 465</b>	<b>Without severe course</b> <b>N = 6,990</b>
<b>Basic characteristics</b>		
Men	260 (55.9%)	3,221 (46.1%)
Age, mean $\pm$ SD	74.8 $\pm$ 13.4	45.4 $\pm$ 20.2
<b>History</b>		
Hypertension	258 (55.5%)	1,266 (18.1%)
Atrial fibrillation	75 (16.1%)	179 (2.6%)
History of stroke	55 (11.8%)	131 (1.9%)
History of MI or PCI	32 (6.9%)	106 (1.5%)
Chronic heart failure	90 (19.4%)	157 (2.2%)
Chronic kidney disease	99 (21.3%)	215 (3.1%)
Diabetes mellitus	127 (27.3%)	519 (7.4%)
Chronic obstructive pulmonary disease	102 (21.9%)	643 (9.2%)
Acid-related disorders	206 (44.3%)	999 (14.3%)
Recent history of cancer ( $\leq$ 5 years)	48 (10.3%)	169 (2.4%)
Rheumatoid arthritis	14 (3.0%)	75 (1.1%)
<b>Treatment</b>		
ACE inhibitors	182 (39.1%)	947 (13.5%)
ARBs	85 (18.3%)	543 (7.8%)
Calcium channel blockers	121 (26.0%)	584 (8.4%)
Beta-blockers	212 (45.6%)	884 (12.6%)
Diuretics	214 (46.0%)	814 (11.6%)
Anticoagulants / antithrombotic agents	143 (30.8%)	502 (7.2%)
Statins	169 (36.3%)	882 (12.6%)


ACE = angiotensin-converting enzyme, ARBs = angiotensin II receptor blockers, MI = myocardial infarction, PCI = percutaneous coronary intervention

**Table 2.** Multivariate logistic regression model using backward stepwise algorithm for selection of independent predictors of severe course of COVID-19. Age, sex and comorbidities from Table 1 were entered into the model.

Predictors		OR (95% CI)	P-value
Sex	Women	Reference category	
	Men	2.10 (1.68; 2.62)	< 0.001
Age	< 40 years	Reference category	
	40–49 years	3.41 (1.37; 8.48)	0.008
	50–59 years	11.92 (5.30; 26.81)	< 0.001
	60–69 years	30.68 (14.04; 67.04)	< 0.001
	70–79 years	60.89 (27.93; 132.73)	< 0.001
	80–89 years	112.68 (51.48; 246.63)	< 0.001
	90+ years	200.12 (86.50; 462.97)	< 0.001
Comorbidities	Chronic kidney disease	1.97 (1.45; 2.68)	< 0.001
	Chronic obstructive pulmonary disease	1.55 (1.17; 2.05)	0.002
	Recent history of cancer ( $\leq 5$ years)	1.54 (1.05; 2.25)	0.026
	Chronic heart failure	1.50 (1.09; 2.08)	0.014
	Acid-related disorders	1.47 (1.16; 1.85)	0.001
	Diabetes mellitus	1.38 (1.07; 1.78)	0.012

Overall predictive power: AUC (95% CI): 0.893 (0.880; 0.907); sensitivity 85.8% and specificity 80.3%.

Figure 1.



**Table S1.** Simplified multivariate logistic regression model based on predictors selected by a backward stepwise algorithm

Predictors		OR (95% CI)	P-value
Sex	Women	Reference category	
	Men	2.10 (1.69; 2.62)	< 0.001
Age	< 40 years	Reference category	
	40–49 years	3.37 (1.36; 8.37)	0.009
	50–59 years	11.69 (5.20; 26.30)	< 0.001
	60–69 years	29.59 (13.56; 64.59)	< 0.001
	70–79 years	59.27 (27.22; 129.05)	< 0.001
	80–89 years	109.93 (50.31; 240.20)	< 0.001
	90+ years	200.66 (86.84; 463.63)	< 0.001
Morbidity level*	1-point increase	1.56 (1.42; 1.72)	< 0.001

\*One point for each comorbidity: chronic kidney disease, chronic obstructive pulmonary disease, recent history of cancer ( $\leq 5$  years), chronic heart failure, acid-related disorders, diabetes mellitus (maximum of 4 points per person, additional points were not considered due to a low prevalence in our cohort).

Overall predictive power: AUC (95% CI): 0.893 (0.879; 0.907); sensitivity 85.8% and specificity 80.3%.

**Table S2.** Characteristics of COVID-19 patients in comparison to general population of the Czech Republic

	COVID-19 patients N = 7,455	General population N = 10.6 million	P-value
<b>Basic characteristics</b>			
Men	46.7%	49.1%	< 0.001
Age, mean ± SD	47.2 ± 21.1	42.5 ± 23.1	< 0.001
<b>Medical history</b>			
Hypertension	20.4%	17.5%	< 0.001
Atrial fibrillation	3.4%	2.3%	< 0.001
History of stroke	2.5%	1.4%	< 0.001
History of MI or PCI	1.9%	1.5%	0.011
Chronic heart failure	3.3%	1.6%	< 0.001
Chronic kidney disease	4.2%	2.4%	< 0.001
Diabetes mellitus	8.7%	7.2%	< 0.001
Chronic obstructive pulmonary disease	10.0%	8.4%	< 0.001
Acid-related disorders	16.2%	11.7%	< 0.001
Recent history of cancer (≤5 years)	2.9%	2.1%	< 0.001
Rheumatoid arthritis	1.2%	0.9%	0.003
<b>Treatment</b>			
ACE inhibitors	15.1%	14.5%	0.100
ARBs	8.4%	7.6%	0.009
Calcium channel blockers	9.5%	8.8%	0.066
Beta-blockers	14.7%	12.0%	< 0.001
Diuretics	13.8%	11.6%	< 0.001
Anticoagulants / antithrombotic agents	8.7%	6.1%	< 0.001
Statins	14.1%	13.9%	0.701

P-value of binomial test (categorical variables) and P-value of one-sample t-test (continuous variables).  
 ACE = angiotensin converting enzyme, ARB = angiotensin II receptor blockers, MI = myocardial infarction,  
 PCI = percutaneous coronary intervention

**Table S3.** Characteristics of COVID-19 patients by using drugs for acid-related disorders


	Using drugs N = 1,205	Not using drugs N = 6,250	P-value
<b>Basic characteristics</b>			
Men	524 (43.5%)	2 957 (47.3%)	<b>0.015</b>
Age, mean $\pm$ SD	62.6 $\pm$ 18.3	44.2 $\pm$ 20.2	<b>&lt; 0.001</b>
<b>Medical history</b>			
Hypertension	542 (45.0%)	982 (15.7%)	<b>&lt; 0.001</b>
Atrial fibrillation	125 (10.4%)	129 (2.1%)	<b>&lt; 0.001</b>
History of stroke	91 (7.6%)	95 (1.5%)	<b>&lt; 0.001</b>
History of MI or PCI	69 (5.7%)	69 (1.1%)	<b>&lt; 0.001</b>
Chronic heart failure	138 (11.5%)	109 (1.7%)	<b>&lt; 0.001</b>
Chronic kidney disease	158 (13.1%)	156 (2.5%)	<b>&lt; 0.001</b>
Diabetes mellitus	222 (18.4%)	424 (6.8%)	<b>&lt; 0.001</b>
Chronic obstructive pulmonary disease	271 (22.5%)	474 (7.6%)	<b>&lt; 0.001</b>
Recent history of cancer ( $\leq$ 5 years)	93 (7.7%)	124 (2.0%)	<b>&lt; 0.001</b>
Rheumatoid arthritis	39 (3.2%)	50 (0.8%)	<b>&lt; 0.001</b>
<b>Treatment</b>			
ACE inhibitors	348 (28.9%)	781 (12.5%)	<b>&lt; 0.001</b>
ARBs	217 (18.0%)	411 (6.6%)	<b>&lt; 0.001</b>
Calcium channel blockers	253 (21.0%)	452 (7.2%)	<b>&lt; 0.001</b>
Beta-blockers	422 (35.0%)	674 (10.8%)	<b>&lt; 0.001</b>
Diuretics	399 (33.1%)	629 (10.1%)	<b>&lt; 0.001</b>
Anticoagulants / antithrombotic agents	270 (22.4%)	375 (6.0%)	<b>&lt; 0.001</b>
Statins	369 (30.6%)	682 (10.9%)	<b>&lt; 0.001</b>

P-value of Fisher's exact test (categorical variables) and P-value of Mann-Whitney U test (continuous variables).

ACE = angiotensin-converting enzyme, ARBs = angiotensin II receptor blockers, MI = myocardial infarction, PCI = percutaneous coronary intervention



Figure S1. Time to analysed endpoint (severe condition)



STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page No
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	4
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	6
Objectives	3	State specific objectives, including any prespecified hypotheses	7
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7,8
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed	7
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8,9
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8,9
Bias	9	Describe any efforts to address potential sources of bias	9
Study size	10	Explain how the study size was arrived at	8,9
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	9,10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses	9,10
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	7,8,10 NA -
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount)	10, Table 1 8 7
Outcome data	15*	Report numbers of outcome events or summary measures over time	10

1	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	10 Table 2
2			(b) Report category boundaries when continuous variables were categorized	
3			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
4				
5				
6				
7				
8				
9	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	11, Table S1,2
10				
11				
12	<b>Discussion</b>			
13	Key results	18	Summarise key results with reference to study objectives	12
14	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	15,16
15				
16				
17	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	13,14
18				
19				
20	Generalisability	21	Discuss the generalisability (external validity) of the study results	16
21				
22	<b>Other information</b>			
23	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	17
24				

25  
26 \*Give information separately for exposed and unexposed groups.

27  
28  
29 **Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# BMJ Open

## Covidogram as a simple tool for predicting severe course of COVID-19: population based study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-045442.R1
Article Type:	Original research
Date Submitted by the Author:	21-Dec-2020
Complete List of Authors:	Jarkovský, Jiří; Masaryk University Institute of Biostatistics and Analyses; Institute of Health Information and Statistics of the Czech Republic Benešová, Klára; Institute of Health Information and Statistics of the Czech Republic; Institute of Health Information and Statistics of the Czech Republic Cerny, Vladimir; Masaryk Hospital in Usti nad Labem, Anesth. and ICU; Dalhousie University, Cerny Vladimir Razova, Jarmila; Ministry of Health of the Czech Republic Kala, petr; Masaryk University; University Hospital Brno Dolina, Jiri; University Hospital Brno; Masaryk University Majek, Ondrej; Institute of Health Information and Statistics of the Czech Republic; Masaryk University Institute of Biostatistics and Analyses Sebestova, Silvie; Institute of Health Information and Statistics of the Czech Republic Bezdekova, Monika; Institute of Health Information and Statistics of the Czech Republic Melicharova, Hana; Institute of Health Information and Statistics of the Czech Republic Snajdrova, Lenka; Institute of Health Information and Statistics of the Czech Republic; Masaryk University Institute of Biostatistics and Analyses Dusek, Ladislav; Institute of Health Information and Statistics of the Czech Republic; Masaryk University Institute of Biostatistics and Analyses Parenica, Jiri; University Hospital Brno, Internal and Cardiology Department; Masaryk University
<b>Primary Subject Heading</b>:	Epidemiology
Secondary Subject Heading:	Epidemiology, Gastroenterology and hepatology
Keywords:	COVID-19, Gastroduodenal disease < GASTROENTEROLOGY, Organisation of health services < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Covidogram as a simple tool for predicting severe course of COVID-19:**  
4  
5  
6 **population based study**  
7  
8  
9

10  
11 Jiri Jarkovsky<sup>1,2</sup>, Klara Benesova<sup>1,2</sup>, Vladimir Cerny<sup>3,4</sup>, Jarmila Razova<sup>5</sup>, Petr  
12  
13 Kala<sup>6,7</sup>, Jiri Dolina<sup>7,8</sup>, Ondrej Majek<sup>1,2</sup>, Silvie Sebestova<sup>1</sup>, Monika Bezdekova<sup>1</sup>,  
14  
15 Hana Melicharova<sup>1</sup>, Lenka Snajdrova<sup>1,2</sup>, Ladislav Dusek<sup>1,2</sup> and Jiri Parenica<sup>1,6,7</sup>  
16  
17  
18

19  
20 <sup>1</sup> Institute of Health Information and Statistics of the Czech Republic, Prague,  
21  
22  
23 Czech Republic  
24

25  
26 <sup>2</sup> Institute of Biostatistics and Analysis, Faculty of Medicine, Masaryk University,  
27  
28  
29 Brno, Czech Republic  
30

31  
32 <sup>3</sup> Department of Anaesthesiology, Perioperative Medicine and Intensive Care,  
33  
34  
35 J.E. Purkinje University, Masaryk Hospital, Usti nad Labem, Czech Republic  
36

37  
38 <sup>4</sup>Department of Anesthesia, Pain Management and Perioperative Medicine,  
39  
40  
41 Dalhousie University, Halifax, Canada  
42

43  
44 <sup>5</sup> Ministry of Health, Czech Republic  
45

46  
47 <sup>6</sup> Internal and Cardiology Department, University Hospital Brno, Czech Republic  
48

49  
50 <sup>7</sup> Faculty of Medicine, Masaryk University, Brno, Czech Republic  
51

52  
53  
54  
55 <sup>8</sup> Gastroenterology and Internal Department, University Hospital Brno, Czech  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

**Key words:** Covid-19; severe course; prognostic score; proton-pump inhibitors

1  
2  
3  
4  
5  
6 **A funding statement** This research received no specific grant from any funding  
7  
8 agency in the public, commercial or not-for-profit sectors  
9

10  
11 **A competing interests statement** All authors have disclosed that they do not  
12  
13 have any conflicts of interest (no support from any organisation for the  
14  
15 submitted work; no financial relationships with any organisations that might  
16  
17 have an interest in the submitted work; no other relationships or activities that  
18  
19 could appear to have influenced the submitted work)  
20  
21  
22

23  
24 **Word count** 2522 (without abstract, tables, references)  
25

26  
27 **Contributors** JJ, LD, VC and JR designed the study and wrote the research plan.  
28  
29 OM, SS, MB, HM extracted the data used for the study from the databases. JJ  
30  
31 and KB undertook statistical analysis with feedback from LD. JP, JJ, PK, JD  
32  
33 interpreted the results and wrote the first draft of the manuscript with critical  
34  
35 comments and revision from VC, LD and LS.  
36  
37  
38  
39  
40  
41

42  
43 **Patient and public involvement** Patients and/or the public were not involved in  
44  
45 the design, or conduct, or reporting, or dissemination plans of this research.  
46  
47

48  
49 **Patient consent for publication** The analysis was done on data from the National  
50  
51 Health Information System (NHIS), which was supplemented with data from the  
52  
53 Information System of Infectious Diseases (ISID). Data in the ISID are collected in  
54  
55 compliance with Act No. 258/2000 Coll. on Protection of Public Health, data in  
56  
57  
58  
59  
60



1  
2  
3 the NHIS are collected – and interconnected with data from ISID – in accordance  
4  
5  
6 with Act No. 372/2011 Coll., on Health Services and Conditions of Their Provision.  
7

8  
9 Due to this legal mandate, the retrospective analyses did not require either  
10  
11 approval by an ethics committee or informed consents from participants.  
12  
13

14 **Data availability statement** The anonymized data available upon reasonable  
15  
16 request. The data are deidentified participant data, and available from the first  
17  
18 author JJ ([jarkovsky@uzis.cz](mailto:jarkovsky@uzis.cz)). The reuse of the data subset is permitted only for  
19  
20 revalidation of the results.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Corresponding author:**  
4

5  
6 Jiri Parenica, MD, MSc, PhD, Professor,  
7

8  
9 Internal and Cardiology Department, University Hospital Brno,  
10

11  
12 Jihlavská 20, 625 00 Brno, Czech Republic  
13

14  
15 e-mail: [jiri.parenica@atlas.cz](mailto:jiri.parenica@atlas.cz)  
16

17  
18 Telephone: +420 53223 2654; Fax: +420 532232907  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

**Objectives** COVID-19 might either be entirely asymptomatic or manifest itself with a large variability of disease severity. It is beneficial to identify early patients with a high risk of severe course. The aim of the analysis was to develop a prognostic model for the prediction of the severe course of acute respiratory infection.

**Design** A population based study.

**Setting** Czech Republic.

**Participants** The first 7,455 consecutive COVID-19 patients who were identified by RT-PCR testing from 1 March 2020 to 17 May 2020.

**Interventions** None

**Primary outcome** Severe course of Covid-19.

**Result** Of a total 6.2% of patients developed a severe course of COVID-19. Age, male sex, chronic kidney disease, chronic obstructive pulmonary disease, recent history of cancer, chronic heart failure, acid-related disorders treated with proton-pump inhibitors and diabetes mellitus were found to be independent negative prognostic factors. (AUC was 0.893). The results were visualised by risk heat maps and we called this diagram a “covidogram”. Acid-related disorders treated with proton-pump inhibitors might represent a negative prognostic factor.

1  
2  
3 **Conclusion** We developed a very simple prediction model called “covidogram”,  
4  
5  
6 which is based on elementary independent variables (age, male sex and the  
7  
8  
9 presence of several chronic diseases) and represents a tool that makes it  
10  
11  
12 possible to identify – with a high reliability – patients who are at risk of a severe  
13  
14  
15 course of COVID-19. Obtained results open clinically relevant question about  
16  
17  
18 the role of acid-related disorders treated by proton pump inhibitors as  
19  
20  
21 predictor for severe course of COVID-19.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Strengths and limitations of the study

- The majority of consecutive patients diagnosed with COVID-19 in the Czech Republic were included in the analysis, regardless of whether they were hospitalized or not.
- The cohort covers also asymptomatic and oligosymptomatic patients identified thanks to epidemiological monitoring.
- The cohort does not include strictly all COVID-19 cases in the Czech Republic because some patients are asymptomatic and have not been tested.
- The proposed prediction model is a simple tool that makes it possible to identify – with a high reliability (AUC 0.893) – patients who are at risk of a severe course of COVID-19.
- Due to the retrospective nature of this study, which is based on data of administrative registries, results of laboratory, clinical and X-ray examinations were not available. Conclusions regarding the influence of comorbidities and the consumption of medicinal products should be interpreted with caution and will require further validation.

## Introduction

The coronavirus disease 2019 (COVID-19) is caused by betacoronavirus SARS-CoV-2, which enters human cells via the membrane-bound angiotensin-converting enzyme 2 (ACE2)[1]. The presence of infection might be entirely asymptomatic[2], or manifest itself with a large variability of disease severity, a number of unspecific clinical symptoms (fever, fatigue, myalgia) and various degrees of organ dysfunction. Most frequently, the disease affects the respiratory system (manifested as dry cough, dyspnoea, haemoptysis, pneumonia or ARDS) and the cardiovascular system (presented as myocardial injury or myocarditis, ventricular arrhythmias, haemodynamic instability or deep vein thrombosis), while other organ systems (such as the central nervous [3], gastrointestinal system or kidneys [4]) are affected less frequently. In a number of patients, there is a risk of multiple organ failure, ultimately leading to death[5–9]. According to the report of World Health Organization, as 12 November 2020, the rate of mortality among COVID-19 patients is 2.28%[10].

The management of COVID-19 patients depends on the disease severity: patients with a mild course of the disease can be treated in their home environment[11]. However, the clinical picture of COVID-19 patients can quickly turn into an unfavourable clinical course [7], and it is therefore clinically relevant to identify patients with a high risk of severe course of the disease as

1  
2  
3 early as possible [12]. It was repeatedly demonstrated that older age > 65,  
4  
5  
6 cancer, chronic obstructive pulmonary disease, moderate-to-severe asthma,  
7  
8  
9 diabetes mellitus, chronic renal disease, immunocompromised state, obesity  
10  
11 (BMI>30), pregnancy, sickle cell disease, smoking and cardiovascular disease  
12  
13  
14 are related to a high-risk course of the disease[7,13–15].  
15  
16

17  
18 In the Czech Republic, a prospective population-based and centralised  
19  
20 collection of data on COVID-19 patients was developed at the beginning of the  
21  
22 pandemic, with a possibility to interconnect these data with those recorded in  
23  
24 other population-based registries of the National Health Information System  
25  
26 (NHIS), and thus to obtain information on each patient's history and  
27  
28  
29 management.  
30  
31  
32  
33

34  
35 The aim of this study was to develop a prognostic model for the  
36  
37 prediction of the severe course of acute respiratory infection, defined by the  
38  
39 necessity of intensive care being provided in the Intensive care units (ICU), that  
40  
41 include mechanical ventilation, extracorporeal membrane oxygenation (ECMO)  
42  
43 support and/or death.  
44  
45  
46  
47  
48  
49  
50

## 51 **Methods**

### 52 ***Population of patients***

53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 The analysis is based on data from a population-based registry containing  
4 records of all consecutive COVID-19 patients in the Czech Republic who were  
5 identified by RT-PCR testing and validated by the National Institute of Public  
6 Health.  
7  
8  
9  
10  
11  
12  
13

14 The monitored cohort consisted of patients who were recorded in the  
15 National Information System of Infectious Diseases (ISID) between 1 March  
16 2020 and 17 May 2020.  
17  
18  
19  
20  
21  
22

23 As of 17 May 2020, a total of 356,515 tests were performed in the Czech  
24 Republic, and the diagnosis of COVID-19 was confirmed in 8,475 cases. Of the  
25 confirmed COVID-19 cases, 464 patients with still unknown history in the  
26 National Health Information System (NHIS) or the patients being foreign  
27 nationals with unknown medical history – were excluded from the analysis, and  
28 further 556 patients with a follow-up period shorter than 14 days. were  
29 excluded as well. 90% of events occur within 14 days (Figure S1). Analysis  
30 without censoring and with a fixed follow-up length was chosen with the  
31 objective to simplify visualisation and interpretation of results of the analysis  
32 for its practical application. The basic characteristics of patients (age, gender)  
33 were provided for all patients, data on comorbidities were available for all  
34 patients with match between COVID19 and health insurance companies  
35 datasets; patients without match between datasets were excluded from the  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 analysis, no other missing data handling was necessary. On top of that,  
4  
5  
6 characteristics of the cohort diagnosed with COVID-19 were compared to those  
7  
8  
9 of the population of the Czech Republic (10.6 million).  
10

### 11 ***Diagnosis***

12  
13  
14 The diagnosis of COVID-19 was based on the detection of SARS-CoV-2 by  
15  
16  
17 real-time reverse transcription polymerase chain reaction (RT-PCR). At first, the  
18  
19  
20 analyses were performed in the National Reference Laboratory of the National  
21  
22  
23 Institute of Public Health (NIPH); other certified laboratories were later  
24  
25  
26 appointed to carry out RT-PCR testing as well.  
27  
28

### 29 ***Systematic collection of data***

30  
31  
32 The analysis was done on data from the National Health Information  
33  
34  
35 System (NHIS), which was supplemented with data from the Information  
36  
37  
38 System of Infectious Diseases (ISID). Data in the ISID are collected in  
39  
40  
41 compliance with Act No. 258/2000 Coll. on Protection of Public Health,  
42  
43  
44 whereas data in the NHIS are collected – and interconnected with data from  
45  
46  
47 ISID – in accordance with Act No. 372/2011 Coll., on Health Services and  
48  
49  
50 Conditions of Their Provision. Due to this legal mandate, the retrospective  
51  
52  
53 analyses did not require either approval by an ethics committee or informed  
54  
55  
56 consents from participants; moreover, it is a population-based analysis of all  
57  
58  
59 diagnosed COVID-19 cases in the Czech Republic. The cohort covers also  
60

1  
2  
3 asymptomatic and oligosymptomatic patients identified thanks to  
4  
5  
6 epidemiological monitoring.  
7

8  
9 The latest data on COVID-19 patients, the severity of their condition as well as  
10  
11 the necessity of hospitalisation in an ICU, including the use of mechanical  
12  
13 ventilation or ECMO, together with information on death, have been entered  
14  
15 into the ISID in real time. Apart from that, data on COVID-19 patients have  
16  
17 been enriched with information on their comorbidities: this information is  
18  
19 available in the National Register of Reimbursed Health Services (NRHZS),  
20  
21 which contains data on all healthcare reported within the public health  
22  
23 insurance system (accounting for almost 100% of healthcare provided in the  
24  
25 Czech Republic). Comorbidities are determined from combinations of reported  
26  
27 diagnoses (ICD-10), ATC codes of drugs, and procedures defined in code lists  
28  
29 used by Czech health insurance companies. Only diseases and conditions with a  
30  
31 higher prevalence in the population or those identified in literature[7,9,15–17]  
32  
33 as potential predictors of a severe course of COVID-19 were evaluated, with the  
34  
35 aim to assess their potential influence on the resulting model.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

### 48 ***Statistical analysis***

49  
50  
51 Standard descriptive statistics were used to describe the data:  
52  
53 categorical variables were described by absolute and relative frequencies,  
54  
55 whereas continuous variables were described by means and standard  
56  
57  
58  
59  
60

1  
2  
3 deviations. The Fisher's exact test (for categorical variables) and Mann–  
4  
5  
6 Whitney U test (for continuous variables) were used to compare characteristics  
7  
8  
9 between groups depending on the monitored endpoint, unless stated  
10  
11  
12 otherwise. The predictive power of patient characteristics with regard to the  
13  
14  
15 analysed endpoint was evaluated by univariate and multivariable logistic  
16  
17  
18 regression and described by odds ratios, their 95% confidence intervals and  
19  
20  
21 statistical significance; a backward stepwise algorithm was used to choose the  
22  
23  
24 optimum model, and a ROC analysis was employed to evaluate the overall  
25  
26  
27 predictive power of the model, Hosmer and Lemeshow test was adopted for  
28  
29  
30 the evaluation of goodness of fit of the model. The results of the model were  
31  
32  
33 expressed by a nomogram in the form of a risk heat map taking account of the  
34  
35  
36 patients' age, sex and comorbidities. A 10-fold cross-validation was performed  
37  
38  
39 to obtain estimates of model performance that are adjusted for in-sample  
40  
41  
42 optimism. A model was created in accordance with TRIPOD check list for  
43  
44  
45 prediction model development and validation [18]. The analysis was computed  
46  
47  
48 using the Vertica database and a MS SQL Server for data pre-processing and  
49  
50  
51 SPSS 25.0.0.1. for the statistical analysis of data. The level of statistical  
52  
53  
54  
55  
56  
57  
58  
59  
60  
significance was set at  $\alpha=0.05$  for all analyses.

## Results

Of the total of 7,455 evaluated patients, 1,182 (15.9%) were hospitalised, 465 of them (6.2%) developed a severe course of the disease (i.e. reached the primary endpoint – the necessity of intensive care being provided in the Intensive care units (ICU), that include mechanical ventilation, ECMO support and/or death), 174 patients (2.3%) required mechanical ventilation, 11 patients (0.1%) were provided ECMO, and 287 patients (3.8%) died. Patients with the monitored endpoint were older ( $74.8 \pm 13.4$  vs  $45.4 \pm 20.2$  years), more frequently of male sex and suffered at least one of all monitored comorbidities (Table 1,  $p < 0.001$  for all parameters; univariable logistic regression results Table S1). Older age was determined by the multivariable logistic regression analysis to be the most significant predictor: the risk of a severe course of the disease increases progressively from the age of 40 years onwards (Table 2). Male sex, chronic kidney disease, chronic obstructive pulmonary disease, recent history of cancer (in the last five years), chronic heart failure, acid related disorders treated with proton-pump inhibitors and diabetes mellitus were other significant predictors; the latter six conditions are hereinafter referred to as **prognostically significant comorbidities** (Table 2). The overall predictive power of the model, evaluated by the C-statistic and expressed by the AUC, was 0.893 (95% CI: 0.880–0.907; sensitivity 85.8% and specificity

1  
2  
3 80.3%). After performing the 10-fold cross-validation to validate the results, the  
4  
5  
6 average AUC of 0.891 (in the range 0.856–0.943) was obtained. For the  
7  
8  
9 purpose of an easier interpretation in clinical practice, a simplified version of  
10  
11  
12 the model was developed, taking into consideration the number of  
13  
14  
15 prognostically significant comorbidities obtained from the previous model  
16  
17  
18 (Table S2). The results were visualised by risk heat maps for men and women  
19  
20  
21 separately (Figure 1), and we called this diagram a “**covidogram**”. The diagram  
22  
23  
24 shows how the risk increases progressively with age and with the number of  
25  
26  
27 prognostically significant comorbidities.

28  
29 It is obvious from the comparison of basic patient characteristics (Table 1) and  
30  
31  
32 the results of the multivariable analysis (Table 2) that although a number of  
33  
34  
35 conditions occur more frequently in the group of patients with a severe course  
36  
37  
38 of the disease, not all of them are independent predictors (coronary artery  
39  
40  
41 disease, history of stroke, atrial fibrillation, hypertension or treatment by ACEIs  
42  
43  
44 and ARBs).

45  
46 The comparison of characteristics of patients with confirmed COVID-19  
47  
48  
49 to those of the entire population of the Czech Republic showed that COVID-19  
50  
51  
52 patients are slightly older and have the monitored comorbidities slightly more  
53  
54  
55 frequently. (Table S3).

## Discussion

### *New findings about COVID-19*

We have developed a prognostic model for the prediction of the severe course of COVID-19 in consecutive patients with positive COVID-19 RT-PCR test. This a simple tool called “covidogram” has a very good predictive power (AUC 0.893). Age is the most significant factor, and the risk increases progressively from the age of 40 years onwards. To our knowledge, this is the first study to suggest that acid related disorders treated by proton pump inhibitors might be independent risk predictors as well. By contrast, not all cardiovascular diseases (such as uncomplicated hypertension or coronary artery disease) increase the risk of a severe course of COVID-19.

The “covidogram” was designed as a model to assess the risk of unfavourable development of the patient’s condition based on his/her history of chronic disease, and can serve as a tool to estimate the number of severe cases of COVID-19 in a population. When assessing the risk for an individual patient in clinical practice, it is certainly necessary to take into consideration also other pieces of information on the current condition of that patient (respiratory rate, peripheral oxygen saturation, level of consciousness, urea level, C reactive protein[19], procalcitonin, aspartate aminotransferase[17], high temperature[16], elevation of cardiac markers, lung infiltrates >50%[9]) as

1  
2  
3 well as obesity, which can also increase the risk of a severe course of COVID-19  
4  
5  
6 [20].  
7

### 8 ***Acid-related disorders***

9  
10 Surprisingly, our analysis revealed that the presence of acid-related  
11  
12 disorders might be theoretically linked to a severe course of COVID-19. Patients  
13  
14 were predominantly treated with proton-pump inhibitors (1,175 patients in  
15  
16 total, out of which 706 were treated with omeprazole and 402 with  
17  
18 pantoprazole as the two most frequently used drugs); only a small proportion  
19  
20 of them were treated with H<sub>2</sub>-receptor antagonists (30 patients). The main  
21  
22 indications for treatment with these drugs generally involve gastro-  
23  
24 oesophageal reflux disease, functional dyspepsia, gastric and duodenal ulcers,  
25  
26 gastric acid hypersecretory states as well as gastroprotection in patients using  
27  
28 non-steroidal anti-inflammatory drugs, dual antiplatelet therapy,  
29  
30 biphosphonates or some selective serotonin reuptake inhibitors (SSRIs). The  
31  
32 effect of inhibition of hydrochloric acid secretion is followed by an increase in  
33  
34 the intragastric pH (to a value above 2–4), which might hypothetically decrease  
35  
36 the physiological bactericidal/virucidal effect of gastric acid and decrease the  
37  
38 activity of lysosomal enzymes. Published data showed that long-term use of  
39  
40 proton-pump inhibitors could slightly increase the risk of pneumonia[21,22]  
41  
42 and enteric infections[23].  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Our comparison of patients with and without acid-related disorders (Table S4)  
4  
5  
6 showed that patients with these disorders are markedly older and have  
7  
8  
9 prognostically significant comorbidities more frequently. Our analysis cannot  
10  
11  
12 determine whether there is any causal relationship between the presence of  
13  
14  
15 acid-related disorders and a severe course of COVID-19 or whether it is just a  
16  
17  
18 coincidence. At the same time, it must be stressed out that the vast majority of  
19  
20  
21 patients were treated with proton-pump inhibitors, not with H<sub>2</sub>-receptor  
22  
23  
24 agonists. The observation is complicated also by the fact that some patients  
25  
26  
27 may not be adherent to their PPI regimen and there was great variability in the  
28  
29  
30 amount of time that they have been on PPIs (from one to twelfth month within  
31  
32  
33 2019). Based on our analysis we are not able to decide whether severity of  
34  
35  
36 disease might be theoretically explained by pharmacology or by underlying  
37  
38  
39 pathology of acid related disorders. Recently, Almario et al. demonstrated  
40  
41  
42 association between using proton pump inhibitors and odds of a positive  
43  
44  
45 COVID-19 test [24]. Similar trend was reported by Tarlow [25].

### 46 **Strengths and limitations**

47  
48  
49 This study is based on a fully integrated national health information  
50  
51  
52 system covering the entire population of a country – which proposed a  
53  
54  
55 prediction model estimating individually-based risk of a severe course of  
56  
57  
58 COVID-19. Because this model uses data readily available in health and  
59  
60



1  
2  
3 administrative registries, it can be easily used for the prediction of intensive  
4  
5  
6 care use in the context of decision-making at the national level.  
7

8  
9 On the other hand, our analysis has a number of limitations. Results of  
10  
11 laboratory, clinical and X-ray examinations performed at the time of patient  
12  
13 admission to hospitals were not available, and these very important pieces of  
14  
15 information could therefore not be analysed; instead, our analysis is based on  
16  
17 administrative data, with the exception of endpoints. Furthermore, analytical  
18  
19 processing of a cohort of patients cannot capture the risk of less frequent  
20  
21 conditions that might increase the risk of a severe course of COVID-19 (e.g.  
22  
23 patients with immunodeficiencies, those after organ transplantation, or those  
24  
25 undergoing immunosuppressive therapy or biological therapy). The cohort  
26  
27 does not include strictly all COVID-19 cases in the Czech Republic because some  
28  
29 patients are asymptomatic and have not been tested. Older peoples with more  
30  
31 comorbidities are probably more likely to have a symptomatic course of COVID-  
32  
33 19. It could be also a reason why the population of patients diagnosed with  
34  
35 COVID-19 is older and with more comorbidities in comparison with the Czech  
36  
37 Republic population (Table S3). Due to the retrospective nature of this study,  
38  
39 which is based on data of administrative registries and is focused on the  
40  
41 development of a prediction model, any conclusions regarding the influence of  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 comorbidities and the consumption of medicinal products should be  
4  
5  
6 interpreted with caution and will require further validation.  
7  
8  
9

## 10 11 **Conclusion**

12  
13  
14 The proposed prediction model “covidogram” is based on elementary  
15  
16 independent variables (age, male sex and the presence of chronic disease) and  
17  
18 represents a simple tool that makes it possible to identify – with a high  
19  
20 reliability (AUC 0.893) – patients who are at risk of a severe course of COVID-  
21  
22  
23  
24  
25  
26 19.

27  
28 Finally, the analysis has shown, for the first time, that acid-related disorders  
29  
30 treated with proton-pump inhibitors might also be theoretically associated with  
31  
32  
33  
34 a severe course of the disease.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

- 1 Hoffmann M, Kleine-Weber H, Schroeder S, *et al.* SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* 2020;**181**:271-280.e8. doi:10.1016/j.cell.2020.02.052
- 2 Sutton D, Fuchs K, D'Alton M, *et al.* Universal Screening for SARS-CoV-2 in Women Admitted for Delivery. *N Engl J Med* Published Online First: 13 April 2020. doi:10.1056/NEJMc2009316
- 3 Aghagoli G, Gallo Marin B, Katchur NJ, *et al.* Neurological Involvement in COVID-19 and Potential Mechanisms: A Review. *Neurocrit Care* 2020;:1–10. doi:10.1007/s12028-020-01049-4
- 4 Aghagoli G, Gallo Marin B, Soliman LB, *et al.* Cardiac involvement in COVID-19 patients: Risk factors, predictors, and complications: A review. *J Card Surg* Published Online First: 19 April 2020. doi:10.1111/jocs.14538
- 5 Giacomelli A, Pezzati L, Conti F, *et al.* Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study. *Clin Infect Dis Off Publ Infect Dis Soc Am* Published Online First: 26 March 2020. doi:10.1093/cid/ciaa330
- 6 Han C, Duan C, Zhang S, *et al.* Digestive Symptoms in COVID-19 Patients With Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes. *Am J Gastroenterol* Published Online First: 15 April 2020. doi:10.14309/ajg.0000000000000664
- 7 Huang C, Wang Y, Li X, *et al.* Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet Lond Engl* 2020;**395**:497–506. doi:10.1016/S0140-6736(20)30183-5
- 8 Kim I-C, Kim JY, Kim HA, *et al.* COVID-19-related myocarditis in a 21-year-old female patient. *Eur Heart J* Published Online First: 13 April 2020. doi:10.1093/eurheartj/ehaa288
- 9 Wang D, Hu B, Hu C, *et al.* Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. *JAMA* 2020;**323**:1061–9. doi:10.1001/jama.2020.1585

- 10 WHO. Coronavirus disease (COVID-19) pandemic. Available from <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>. Accessed 12 Dec 2020.
- 11 Gandhi RT, Lynch JB, Rio C del. Mild or Moderate Covid-19. *N Engl J Med* Published Online First: 24 April 2020. doi:10.1056/NEJMcp2009249
- 12 Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. *N Engl J Med* 2020;**0**:null. doi:10.1056/NEJMcp2009575
- 13 Mehra MR, Desai SS, Kuy S, *et al*. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. *N Engl J Med* Published Online First: 1 May 2020. doi:10.1056/NEJMoa2007621
- 14 Wang T, Tang C, Chen R, *et al*. Clinical Features of Coronavirus Disease 2019 Patients With Mechanical Ventilation: A Nationwide Study in China. *Crit Care Med* 2020;**Online First**. doi:10.1097/CCM.0000000000004473
- 15 CDC, Coronavirus-19. Available from <https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html>.
- 16 Wu C, Chen X, Cai Y, *et al*. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med* Published Online First: 13 March 2020. doi:10.1001/jamainternmed.2020.0994
- 17 Chen R, Liang W, Jiang M, *et al*. Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China. *Chest* Published Online First: 15 April 2020. doi:10.1016/j.chest.2020.04.010
- 18 Collins Gary S., Reitsma Johannes B., Altman Douglas G., *et al*. Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD). *Circulation* 2015;**131**:211–9. doi:10.1161/CIRCULATIONAHA.114.014508
- 19 Knight SR, Ho A, Pius R, *et al*. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. *BMJ* 2020;**370**. doi:10.1136/bmj.m3339

- 1  
2  
3 20 Malik P, Patel U, Patel K, *et al.* Obesity a predictor of outcomes of COVID-19  
4 hospitalized patients- A systematic Review and Meta-Analysis. *J Med Virol*  
5 Published Online First: 25 September 2020. doi:10.1002/jmv.26555  
6  
7  
8 21 Eom C-S, Jeon CY, Lim J-W, *et al.* Use of acid-suppressive drugs and risk of  
9 pneumonia: a systematic review and meta-analysis. *CMAJ Can Med Assoc J J*  
10 *Assoc Medicale Can* 2011;**183**:310–9. doi:10.1503/cmaj.092129  
11  
12  
13 22 Zirk-Sadowski J, Masoli JA, Delgado J, *et al.* Proton-Pump Inhibitors and  
14 Long-Term Risk of Community-Acquired Pneumonia in Older Adults. *J Am*  
15 *Geriatr Soc* 2018;**66**:1332–8. doi:10.1111/jgs.15385  
16  
17  
18 23 Moayyedi P, Eikelboom JW, Bosch J, *et al.* Safety of Proton Pump Inhibitors  
19 Based on a Large, Multi-Year, Randomized Trial of Patients Receiving  
20 Rivaroxaban or Aspirin. *Gastroenterology* 2019;**157**:682-691.e2.  
21 doi:10.1053/j.gastro.2019.05.056  
22  
23  
24 24 Almario CV, Chey WD, Spiegel BMR. Increased Risk of COVID-19 Among  
25 Users of Proton Pump Inhibitors. *Am J Gastroenterol* Published Online First:  
26 25 August 2020. doi:10.14309/ajg.0000000000000798  
27  
28  
29 25 Tarlow B, Gubatan J, Khan MA, *et al.* Are Proton Pump Inhibitors  
30 Contributing to SARS-COV-2 Infection? *Off J Am Coll Gastroenterol ACG*  
31 2020;**Publish Ahead of Print**. doi:10.14309/ajg.0000000000000933  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Figure legend**  
4

5  
6 Figure 1. COVIDOGRAM – predicted probability of severe course of Covid-19 for  
7  
8 men and women – visualization of simplified multivariable logistic regression  
9  
10  
11 model (for more details, see Supplemental Table 1)  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

**Table 1.** Characteristics of COVID-19 patients according to endpoint

	<b>With severe course</b> <b>N = 465</b>	<b>Without severe course</b> <b>N = 6,990</b>
<b>Basic characteristics</b>		
Men	260 (55.9%)	3,221 (46.1%)
Age, mean $\pm$ SD	74.8 $\pm$ 13.4	45.4 $\pm$ 20.2
<b>History</b>		
Hypertension	258 (55.5%)	1,266 (18.1%)
Atrial fibrillation	75 (16.1%)	179 (2.6%)
History of stroke	55 (11.8%)	131 (1.9%)
History of MI or PCI	32 (6.9%)	106 (1.5%)
Chronic heart failure	90 (19.4%)	157 (2.2%)
Chronic kidney disease	99 (21.3%)	215 (3.1%)
Diabetes mellitus	127 (27.3%)	519 (7.4%)
Chronic obstructive pulmonary disease	102 (21.9%)	643 (9.2%)
Acid-related disorders	206 (44.3%)	999 (14.3%)
Recent history of cancer ( $\leq$ 5 years)	48 (10.3%)	169 (2.4%)
Rheumatoid arthritis	14 (3.0%)	75 (1.1%)
<b>Treatment</b>		
ACE inhibitors	182 (39.1%)	947 (13.5%)
ARBs	85 (18.3%)	543 (7.8%)
Calcium channel blockers	121 (26.0%)	584 (8.4%)
Beta-blockers	212 (45.6%)	884 (12.6%)
Diuretics	214 (46.0%)	814 (11.6%)
Anticoagulants / antithrombotic agents	143 (30.8%)	502 (7.2%)
Statins	169 (36.3%)	882 (12.6%)

ACE = angiotensin-converting enzyme, ARBs = angiotensin II receptor blockers, MI = myocardial infarction, PCI = percutaneous coronary intervention

**Table 2.** Multivariable logistic regression model using backward stepwise algorithm for selection of independent predictors of severe course of COVID-19. Age, sex and comorbidities from Table 1 were entered into the model.


Predictors	Regression coefficients	SE	OR (95% CI)	P-value
<b>Sex</b>				
Women			Reference category	
Men	0.742	0.112	2.10 (1.68; 2.62)	< 0.001
<b>Age</b>				
< 40 years			Reference category	
40–49 years	1.227	0.464	3.41 (1.37; 8.48)	0.008
50–59 years	2.478	0.414	11.92 (5.30; 26.81)	< 0.001
60–69 years	3.424	0.399	30.68 (14.04; 67.04)	< 0.001
70–79 years	4.109	0.398	60.89 (27.93; 132.73)	< 0.001
80–89 years	4.725	0.400	112.68 (51.48; 246.63)	< 0.001
90+ years	5.299	0.428	200.12 (86.50; 462.97)	< 0.001
<b>Comorbidities</b>				
Chronic kidney disease	0.679	0.157	1.97 (1.45; 2.68)	< 0.001
Chronic obstructive pulmonary disease	0.436	0.144	1.55 (1.17; 2.05)	0.002
Recent history of cancer (≤5 years)	0.432	0.194	1.54 (1.05; 2.25)	0.026
Chronic heart failure	0.408	0.166	1.50 (1.09; 2.08)	0.014
Acid-related disorders	0.382	0.118	1.47 (1.16; 1.85)	0.001
Diabetes mellitus	0.323	0.129	1.38 (1.07; 1.78)	0.012
<b>Intercept</b>	-6.448	0.386	-	< 0.001

Hosmer and Lemeshow test:  $\chi^2 = 9.315$ , df = 8, p = 0.316;

overall predictive power: AUC (95% CI): 0.893 (0.880; 0.907); sensitivity 85.8% and specificity 80.3%.



Figure 1.



**Table S1.** Univariable logistic regression models

	<u>Regression coefficients</u>	<u>SE</u>	<u>OR (95% CI)</u>	<u>P-value</u>
<b>Basic characteristics</b>				
<u>Sex – men (ref. women)</u>	<u>0.395</u>	<u>0.096</u>	<u>1.48 (1.23; 1.79)</u>	<u>&lt; 0.001</u>
<u>Age 40–49 years (ref. &lt; 40 years)</u>	<u>1.260</u>	<u>0.464</u>	<u>3.52 (1.42; 8.75)</u>	<u>0.007</u>
<u>Age 50–59 years (ref. &lt; 40 years)</u>	<u>2.553</u>	<u>0.413</u>	<u>12.84 (5.72; 28.85)</u>	<u>&lt; 0.001</u>
<u>Age 60–69 years (ref. &lt; 40 years)</u>	<u>3.716</u>	<u>0.396</u>	<u>41.09 (18.93; 89.20)</u>	<u>&lt; 0.001</u>
<u>Age 70–79 years (ref. &lt; 40 years)</u>	<u>4.584</u>	<u>0.391</u>	<u>97.92 (45.52; 210.66)</u>	<u>&lt; 0.001</u>
<u>Age 80–89 years (ref. &lt; 40 years)</u>	<u>5.096</u>	<u>0.392</u>	<u>163.44 (75.80; 352.40)</u>	<u>&lt; 0.001</u>
<u>Age 90+ years (ref. &lt; 40 years)</u>	<u>5.555</u>	<u>0.418</u>	<u>258.59 (113.92; 586.98)</u>	<u>&lt; 0.001</u>
<b>History</b>				
<u>Hypertension</u>	<u>1.729</u>	<u>0.098</u>	<u>5.64 (4.65; 6.83)</u>	<u>&lt; 0.001</u>
<u>Atrial fibrillation</u>	<u>1.990</u>	<u>0.147</u>	<u>7.32 (5.48; 9.76)</u>	<u>&lt; 0.001</u>
<u>History of stroke</u>	<u>1.949</u>	<u>0.169</u>	<u>7.02 (5.05; 9.77)</u>	<u>&lt; 0.001</u>
<u>History of MI or PCI</u>	<u>1.569</u>	<u>0.208</u>	<u>4.80 (3.19; 7.21)</u>	<u>&lt; 0.001</u>
<u>Chronic heart failure</u>	<u>2.346</u>	<u>0.142</u>	<u>10.45 (7.90; 13.81)</u>	<u>&lt; 0.001</u>
<u>Chronic kidney disease</u>	<u>2.143</u>	<u>0.133</u>	<u>8.52 (6.57; 11.06)</u>	<u>&lt; 0.001</u>
<u>Diabetes mellitus</u>	<u>1.544</u>	<u>0.114</u>	<u>4.68 (3.75; 5.85)</u>	<u>&lt; 0.001</u>
<u>Chronic obstructive pulmonary disease</u>	<u>1.020</u>	<u>0.119</u>	<u>2.77 (2.19; 3.51)</u>	<u>&lt; 0.001</u>
<u>Acid-related disorders</u>	<u>1.562</u>	<u>0.099</u>	<u>4.77 (3.93; 5.80)</u>	<u>&lt; 0.001</u>
<u>Recent history of cancer (≤ 5 years)</u>	<u>1.536</u>	<u>0.171</u>	<u>4.65 (3.32; 6.50)</u>	<u>&lt; 0.001</u>
<u>Rheumatoid arthritis</u>	<u>1.052</u>	<u>0.295</u>	<u>2.86 (1.60; 5.10)</u>	<u>&lt; 0.001</u>
<b>Treatment</b>				
<u>ACE inhibitors</u>	<u>1.412</u>	<u>0.101</u>	<u>4.10 (3.37; 5.00)</u>	<u>&lt; 0.001</u>
<u>ARBs</u>	<u>0.977</u>	<u>0.128</u>	<u>2.66 (2.07; 3.41)</u>	<u>&lt; 0.001</u>
<u>Calcium channel blockers</u>	<u>1.350</u>	<u>0.114</u>	<u>3.86 (3.08; 4.83)</u>	<u>&lt; 0.001</u>
<u>Beta-blockers</u>	<u>1.756</u>	<u>0.100</u>	<u>5.79 (4.76; 7.04)</u>	<u>&lt; 0.001</u>
<u>Diuretics</u>	<u>1.867</u>	<u>0.100</u>	<u>6.47 (5.31; 7.87)</u>	<u>&lt; 0.001</u>
<u>Anticoagulants / antithrombotic agents</u>	<u>1.747</u>	<u>0.111</u>	<u>5.74 (4.62; 7.13)</u>	<u>&lt; 0.001</u>
<u>Statins</u>	<u>1.375</u>	<u>0.103</u>	<u>3.95 (3.23; 4.84)</u>	<u>&lt; 0.001</u>

**Table S24.** Simplified multivariable logistic regression model based on predictors selected by a backward stepwise algorithm

<b>Predictors</b>	<b>Regression coefficients</b>	<b>SE</b>	<b>OR (95% CI)</b>	<b>P-value</b>
<b>Sex</b>				
Women			Reference category	
Men	<u>0.744</u>	<u>0.112</u>	<u>2.10 (1.69; 2.62)</u>	<u>&lt; 0.001</u>
<b>Age</b>				
< 40 years			Reference category	
40–49 years	<u>1.215</u>	<u>0.464</u>	<u>3.37 (1.36; 8.37)</u>	<u>0.009</u>
50–59 years	<u>2.459</u>	<u>0.414</u>	<u>11.69 (5.20; 26.30)</u>	<u>&lt; 0.001</u>
60–69 years	<u>3.388</u>	<u>0.398</u>	<u>29.59 (13.56; 64.59)</u>	<u>&lt; 0.001</u>
70–79 years	<u>4.082</u>	<u>0.397</u>	<u>59.27 (27.22; 129.05)</u>	<u>&lt; 0.001</u>
80–89 years	<u>4.700</u>	<u>0.399</u>	<u>109.93 (50.31; 240.20)</u>	<u>&lt; 0.001</u>
90+ years	<u>5.302</u>	<u>0.427</u>	<u>200.66 (86.84; 463.63)</u>	<u>&lt; 0.001</u>
<b>Morbidity level*</b>				
1-point increase	<u>0.448</u>	<u>0.049</u>	<u>1.56 (1.42; 1.72)</u>	<u>&lt; 0.001</u>
<b>Intercept</b>	<u>-6.453</u>	<u>0.386</u>		<u>&lt; 0.001</u>

Hosmer and Lemeshow test:  $\chi^2 = 10.310$ , df = 8, p = 0.244;

overall predictive power: AUC (95% CI): 0.893 (0.879; 0.907); sensitivity 85.8% and specificity 80.3%.

\*One point for each comorbidity: chronic kidney disease, chronic obstructive pulmonary disease, recent history of cancer ( $\leq 5$  years), chronic heart failure, acid-related disorders, diabetes mellitus (maximum of 4 points per person, additional points were not considered due to a low prevalence in our cohort).

**Table S32.** Characteristics of COVID-19 patients in comparison to general population of the Czech Republic

	COVID-19 patients N = 7,455	General population N = 10.6 million	P-value
<b>Basic characteristics</b>			
Men	46.7%	49.1%	< 0.001
Age, mean ± SD	47.2 ± 21.1	42.5 ± 23.1	< 0.001
<b>Medical history</b>			
Hypertension	20.4%	17.5%	< 0.001
Atrial fibrillation	3.4%	2.3%	< 0.001
History of stroke	2.5%	1.4%	< 0.001
History of MI or PCI	1.9%	1.5%	0.011
Chronic heart failure	3.3%	1.6%	< 0.001
Chronic kidney disease	4.2%	2.4%	< 0.001
Diabetes mellitus	8.7%	7.2%	< 0.001
Chronic obstructive pulmonary disease	10.0%	8.4%	< 0.001
Acid-related disorders	16.2%	11.7%	< 0.001
Recent history of cancer (≤5 years)	2.9%	2.1%	< 0.001
Rheumatoid arthritis	1.2%	0.9%	0.003
<b>Treatment</b>			
ACE inhibitors	15.1%	14.5%	0.100
ARBs	8.4%	7.6%	0.009
Calcium channel blockers	9.5%	8.8%	0.066
Beta-blockers	14.7%	12.0%	< 0.001
Diuretics	13.8%	11.6%	< 0.001
Anticoagulants / antithrombotic agents	8.7%	6.1%	< 0.001
Statins	14.1%	13.9%	0.701

P-value of binomial test (categorical variables) and P-value of one-sample t-test (continuous variables).  
 ACE = angiotensin converting enzyme, ARB = angiotensin II receptor blockers, MI = myocardial infarction,  
 PCI = percutaneous coronary intervention


**Table S43.** Characteristics of COVID-19 patients by using drugs for acid-related disorders

	Using drugs N = 1,205	Not using drugs N = 6,250	P-value
<b>Basic characteristics</b>			
Men	524 (43.5%)	2 957 (47.3%)	<b>0.015</b>
Age, mean ± SD	62.6 ± 18.3	44.2 ± 20.2	<b>&lt; 0.001</b>
<b>Medical history</b>			
Hypertension	542 (45.0%)	982 (15.7%)	<b>&lt; 0.001</b>
Atrial fibrillation	125 (10.4%)	129 (2.1%)	<b>&lt; 0.001</b>
History of stroke	91 (7.6%)	95 (1.5%)	<b>&lt; 0.001</b>
History of MI or PCI	69 (5.7%)	69 (1.1%)	<b>&lt; 0.001</b>
Chronic heart failure	138 (11.5%)	109 (1.7%)	<b>&lt; 0.001</b>
Chronic kidney disease	158 (13.1%)	156 (2.5%)	<b>&lt; 0.001</b>
Diabetes mellitus	222 (18.4%)	424 (6.8%)	<b>&lt; 0.001</b>
Chronic obstructive pulmonary disease	271 (22.5%)	474 (7.6%)	<b>&lt; 0.001</b>
Recent history of cancer (≤5 years)	93 (7.7%)	124 (2.0%)	<b>&lt; 0.001</b>
Rheumatoid arthritis	39 (3.2%)	50 (0.8%)	<b>&lt; 0.001</b>
<b>Treatment</b>			
ACE inhibitors	348 (28.9%)	781 (12.5%)	<b>&lt; 0.001</b>
ARBs	217 (18.0%)	411 (6.6%)	<b>&lt; 0.001</b>
Calcium channel blockers	253 (21.0%)	452 (7.2%)	<b>&lt; 0.001</b>
Beta-blockers	422 (35.0%)	674 (10.8%)	<b>&lt; 0.001</b>
Diuretics	399 (33.1%)	629 (10.1%)	<b>&lt; 0.001</b>
Anticoagulants / antithrombotic agents	270 (22.4%)	375 (6.0%)	<b>&lt; 0.001</b>
Statins	369 (30.6%)	682 (10.9%)	<b>&lt; 0.001</b>

P-value of Fisher's exact test (categorical variables) and P-value of Mann-Whitney U test (continuous variables).

ACE = angiotensin-converting enzyme, ARBs = angiotensin II receptor blockers, MI = myocardial infarction, PCI = percutaneous coronary intervention

Figure S1. Time to analysed endpoint (severe condition)



## TRIPOD Checklist: Prediction Model Development and Validation

Section/Topic	Item	Checklist Item	Page	
<b>Title and abstract</b>				
Title	1	D;V	Identify the study as developing and/or validating a multivariable prediction model, the target population, and the outcome to be predicted.	1
Abstract	2	D;V	Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, statistical analysis, results, and conclusions.	5
<b>Introduction</b>				
Background and objectives	3a	D;V	Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models.	8
	3b	D;V	Specify the objectives, including whether the study describes the development or validation of the model or both.	9
<b>Methods</b>				
Source of data	4a	D;V	Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for the development and validation data sets, if applicable.	10
	4b	D;V	Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow-up.	10
Participants	5a	D;V	Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centres.	11
	5b	D;V	Describe eligibility criteria for participants.	10
	5c	D;V	Give details of treatments received, if relevant.	-
Outcome	6a	D;V	Clearly define the outcome that is predicted by the prediction model, including how and when assessed.	14
	6b	D;V	Report any actions to blind assessment of the outcome to be predicted.	-
Predictors	7a	D;V	Clearly define all predictors used in developing or validating the multivariable prediction model, including how and when they were measured.	12
	7b	D;V	Report any actions to blind assessment of predictors for the outcome and other predictors.	-
Sample size	8	D;V	Explain how the study size was arrived at.	10
Missing data	9	D;V	Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method.	10
Statistical analysis methods	10a	D	Describe how predictors were handled in the analyses.	12
	10b	D	Specify type of model, all model-building procedures (including any predictor selection), and method for internal validation.	13
	10c	V	For validation, describe how the predictions were calculated.	13
	10d	D;V	Specify all measures used to assess model performance and, if relevant, to compare multiple models.	13
	10e	V	Describe any model updating (e.g., recalibration) arising from the validation, if done.	-
Risk groups	11	D;V	Provide details on how risk groups were created, if done.	-
Development vs. validation	12	V	For validation, identify any differences from the development data in setting, eligibility criteria, outcome, and predictors.	-
<b>Results</b>				
Participants	13a	D;V	Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful.	10
	13b	D;V	Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome.	T1
	13c	V	For validation, show a comparison with the development data of the distribution of important variables (demographics, predictors and outcome).	-
Model development	14a	D	Specify the number of participants and outcome events in each analysis.	14
	14b	D	If done, report the unadjusted association between each candidate predictor and outcome.	S4
Model specification	15a	D	Present the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point).	T2, S1
	15b	D	Explain how to use the prediction model.	F1
Model performance	16	D;V	Report performance measures (with CIs) for the prediction model.	14
Model-updating	17	V	If done, report the results from any model updating (i.e., model specification, model performance).	-
<b>Discussion</b>				
Limitations	18	D;V	Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data).	19
Interpretation	19a	V	For validation, discuss the results with reference to performance in the development data, and any other validation data.	-
	19b	D;V	Give an overall interpretation of the results, considering objectives, limitations, results from similar studies, and other relevant evidence.	19
Implications	20	D;V	Discuss the potential clinical use of the model and implications for future research.	20
<b>Other information</b>				
Supplementary information	21	D;V	Provide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets.	3
Funding	22	D;V	Give the source of funding and the role of the funders for the present study.	2

\*Items relevant only to the development of a prediction model are denoted by D, items relating solely to a validation of a prediction model are denoted by V, and items relating to both are denoted D;V. We recommend using the TRIPOD Checklist in conjunction with the TRIPOD Explanation and Elaboration document.

# BMJ Open

## Covidogram as a simple tool for predicting severe course of COVID-19: population based study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-045442.R2
Article Type:	Original research
Date Submitted by the Author:	20-Jan-2021
Complete List of Authors:	Jarkovský, Jiří; Masaryk University Institute of Biostatistics and Analyses; Institute of Health Information and Statistics of the Czech Republic Benešová, Klára; Institute of Health Information and Statistics of the Czech Republic; Institute of Health Information and Statistics of the Czech Republic Cerny, Vladimir; Masaryk Hospital in Usti nad Labem, Anesth. and ICU; Dalhousie University, Cerny Vladimir Razova, Jarmila; Ministry of Health of the Czech Republic Kala, petr; Masaryk University; University Hospital Brno Dolina, Jiri; University Hospital Brno; Masaryk University Majek, Ondrej; Institute of Health Information and Statistics of the Czech Republic; Masaryk University Institute of Biostatistics and Analyses Sebestova, Silvie; Institute of Health Information and Statistics of the Czech Republic Bezdekova, Monika; Institute of Health Information and Statistics of the Czech Republic Melicharova, Hana; Institute of Health Information and Statistics of the Czech Republic Snajdrova, Lenka; Institute of Health Information and Statistics of the Czech Republic; Masaryk University Institute of Biostatistics and Analyses Dusek, Ladislav; Institute of Health Information and Statistics of the Czech Republic; Masaryk University Institute of Biostatistics and Analyses Parenica, Jiri; University Hospital Brno; Masaryk University Faculty of Medicine
<b>Primary Subject Heading</b>:	Epidemiology
Secondary Subject Heading:	Epidemiology, Gastroenterology and hepatology
Keywords:	COVID-19, Gastroduodenal disease < GASTROENTEROLOGY, Organisation of health services < HEALTH SERVICES ADMINISTRATION & MANAGEMENT



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Covidogram as a simple tool for predicting severe course of COVID-19:**  
4  
5  
6 **population based study**  
7  
8  
9

10  
11 Jiri Jarkovsky<sup>1,2</sup>, Klara Benesova<sup>1,2</sup>, Vladimir Cerny<sup>3,4</sup>, Jarmila Razova<sup>5</sup>, Petr  
12  
13 Kala<sup>6,7</sup>, Jiri Dolina<sup>7,8</sup>, Ondrej Majek<sup>1,2</sup>, Silvie Sebestova<sup>1</sup>, Monika Bezdekova<sup>1</sup>,  
14  
15 Hana Melicharova<sup>1</sup>, Lenka Snajdrova<sup>1,2</sup>, Ladislav Dusek<sup>1,2</sup> and Jiri Parenica<sup>1,6,7</sup>  
16  
17  
18

19  
20 <sup>1</sup> Institute of Health Information and Statistics of the Czech Republic, Prague,  
21  
22  
23 Czech Republic  
24

25  
26 <sup>2</sup> Institute of Biostatistics and Analysis, Faculty of Medicine, Masaryk University,  
27  
28  
29 Brno, Czech Republic  
30

31  
32 <sup>3</sup> Department of Anaesthesiology, Perioperative Medicine and Intensive Care,  
33  
34  
35 J.E. Purkinje University, Masaryk Hospital, Usti nad Labem, Czech Republic  
36

37  
38 <sup>4</sup>Department of Anesthesia, Pain Management and Perioperative Medicine,  
39  
40  
41 Dalhousie University, Halifax, Canada  
42

43  
44 <sup>5</sup> Ministry of Health, Czech Republic  
45

46  
47 <sup>6</sup> Internal and Cardiology Department, University Hospital Brno, Czech Republic  
48

49  
50 <sup>7</sup> Faculty of Medicine, Masaryk University, Brno, Czech Republic  
51

52  
53  
54  
55 <sup>8</sup> Gastroenterology and Internal Department, University Hospital Brno, Czech  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

**Key words:** Covid-19; severe course; prognostic score; proton-pump inhibitors

1  
2  
3  
4  
5  
6 **A funding statement** This research was supported by grant the Czech Republic  
7  
8 Operational Programme eHealth and Rare Disease CZ.03.4.74/0.0/0.0/15\_025/  
9

10  
11 **Word count** 2565 (without abstract, tables, references)  
12

13  
14 **Contributors** JJ, LD, VC and JR designed the study and wrote the research plan.  
15

16  
17 OM, SS, MB and HM extracted the data used for the study from the databases.  
18

19  
20 JJ and KB undertook statistical analysis with feedback from LD. JP, JJ, PK, JD  
21

22  
23 interpreted the results and wrote the first draft of the manuscript with critical  
24  
25 comments and revision from VC, LD and LS.  
26  
27

28  
29 **Patient and public involvement** Patients and/or the public were not involved in  
30  
31 the design, or conduct, or reporting, or dissemination plans of this research.  
32  
33

34  
35 **Patient consent for publication** The analysis was done on data from the National  
36  
37 Health Information System (NHIS), which was supplemented with data from the  
38  
39 Information System of Infectious Diseases (ISID). Data in the ISID are collected in  
40  
41 compliance with Act No. 258/2000 Coll. on Protection of Public Health, data in  
42  
43 the NHIS are collected – and interconnected with data from ISID – in accordance  
44  
45 with Act No. 372/2011 Coll., on Health Services and Conditions of Their Provision.  
46  
47  
48  
49 Due to this legal mandate, the retrospective analyses did not require either  
50  
51 approval by an ethics committee or informed consents from participants.  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Data availability statement** The anonymized data available upon reasonable  
4  
5  
6 request. The data are deidentified participant data, and available from the first  
7  
8  
9 author JJ ([jarkovsky@uzis.cz](mailto:jarkovsky@uzis.cz)). The reuse of the data subset is permitted only for  
10  
11  
12 revalidation of the results.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1  
2  
3 **Corresponding author:**  
4

5  
6 Jiri Parenica, MD, MSc, PhD, Professor,  
7

8  
9 University Hospital Brno, Brno, Jihomoravský, CZ and Masaryk University Faculty  
10

11  
12 of Medicine Brno, Jihomoravský, CZ  
13

14  
15 e-mail: [jiri.parenica@atlas.cz](mailto:jiri.parenica@atlas.cz)  
16

17  
18 Telephone: +420 53223 2654; Fax: +420 532232907  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

**Objectives** COVID-19 might either be entirely asymptomatic or manifest itself with a large variability of disease severity. It is beneficial to identify early patients with a high risk of severe course. The aim of the analysis was to develop a prognostic model for the prediction of the severe course of acute respiratory infection.

**Design** A population based study.

**Setting** Czech Republic.

**Participants** The first 7,455 consecutive COVID-19 patients who were identified by RT-PCR testing from 1 March 2020 to 17 May 2020.

**Interventions** None

**Primary outcome** Severe course of Covid-19.

**Result** Of a total 6.2% of patients developed a severe course of COVID-19. Age, male sex, chronic kidney disease, chronic obstructive pulmonary disease, recent history of cancer, chronic heart failure, acid-related disorders treated with proton-pump inhibitors and diabetes mellitus were found to be independent negative prognostic factors. (AUC was 0.893). The results were visualised by risk heat maps and we called this diagram a “covidogram”. Acid-related disorders treated with proton-pump inhibitors might represent a negative prognostic factor.

1  
2  
3 **Conclusion** We developed a very simple prediction model called “covidogram”,  
4  
5  
6 which is based on elementary independent variables (age, male sex and the  
7  
8  
9 presence of several chronic diseases) and represents a tool that makes it  
10  
11  
12 possible to identify – with a high reliability – patients who are at risk of a severe  
13  
14  
15 course of COVID-19. Obtained results open clinically relevant question about  
16  
17  
18 the role of acid-related disorders treated by proton pump inhibitors as  
19  
20  
21 predictor for severe course of COVID-19.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Strengths and limitations of the study

- The majority of consecutive patients diagnosed with COVID-19 in the Czech Republic were included in the analysis, regardless of whether they were hospitalized or not.
- The cohort covers also asymptomatic and oligosymptomatic patients identified thanks to epidemiological monitoring.
- The cohort does not include strictly all COVID-19 cases in the Czech Republic because some patients are asymptomatic and have not been tested.
- The proposed prediction model is a simple tool that makes it possible to identify – with a high reliability (AUC 0.893) – patients who are at risk of a severe course of COVID-19.
- Flexible calibration curves based on local regression confirm the predictive model is well-calibrated. The out of sample calibration is currently not available as data of large sample of patients from the second wave COVID-19 in the Czech Republic are still under preparation.
- Due to the retrospective nature of this study, which is based on data of administrative registries, results of laboratory, clinical and X-ray examinations were not available. Conclusions regarding the influence of

1  
2  
3 comorbidities and the consumption of medicinal products should be  
4  
5  
6 interpreted with caution and will require further validation.  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## Introduction

The coronavirus disease 2019 (COVID-19) is caused by betacoronavirus SARS-CoV-2, which enters human cells via the membrane-bound angiotensin-converting enzyme 2 (ACE2)[1]. The presence of infection might be entirely asymptomatic[2], or manifest itself with a large variability of disease severity, a number of unspecific clinical symptoms (fever, fatigue, myalgia) and various degrees of organ dysfunction. Most frequently, the disease affects the respiratory system (manifested as dry cough, dyspnoea, haemoptysis, pneumonia or ARDS) and the cardiovascular system (presented as myocardial injury or myocarditis, ventricular arrhythmias, haemodynamic instability or deep vein thrombosis), while other organ systems (such as the central nervous [3], gastrointestinal system or kidneys [4]) are affected less frequently. In a number of patients, there is a risk of multiple organ failure, ultimately leading to death[5–9]. According to the report of World Health Organization, as 12 November 2020, the rate of mortality among COVID-19 patients is 2.28%[10].

The management of COVID-19 patients depends on the disease severity: patients with a mild course of the disease can be treated in their home environment[11]. However, the clinical picture of COVID-19 patients can quickly turn into an unfavourable clinical course [7], and it is therefore clinically relevant to identify patients with a high risk of severe course of the disease as

1  
2  
3 early as possible [12]. It was repeatedly demonstrated that older age > 65,  
4  
5  
6 cancer, chronic obstructive pulmonary disease, moderate-to-severe asthma,  
7  
8  
9 diabetes mellitus, chronic renal disease, immunocompromised state, obesity  
10  
11  
12 (BMI>30), pregnancy, sickle cell disease, smoking and cardiovascular disease  
13  
14  
15 are related to a high-risk course of the disease[7,13–15].  
16

17  
18 In the Czech Republic, a prospective population-based and centralised  
19  
20 collection of data on COVID-19 patients was developed at the beginning of the  
21  
22 pandemic, with a possibility to interconnect these data with those recorded in  
23  
24 other population-based registries of the National Health Information System  
25  
26 (NHIS), and thus to obtain information on each patient's history and  
27  
28  
29 management.  
30  
31  
32  
33

34  
35 The aim of this study was to develop a prognostic model for the  
36  
37 prediction of the severe course of acute respiratory infection, defined by the  
38  
39 necessity of intensive care being provided in the Intensive care units (ICU), that  
40  
41 include mechanical ventilation, extracorporeal membrane oxygenation (ECMO)  
42  
43 support and/or death.  
44  
45  
46  
47  
48  
49  
50

## 51 **Methods**

### 52 ***Population of patients***

53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 The analysis is based on data from a population-based registry containing  
4 records of all consecutive COVID-19 patients in the Czech Republic who were  
5 identified by RT-PCR testing and validated by the National Institute of Public  
6 Health.  
7  
8  
9  
10  
11  
12  
13

14 The monitored cohort consisted of patients who were recorded in the  
15 National Information System of Infectious Diseases (ISID) between 1 March  
16 2020 and 17 May 2020.  
17  
18  
19  
20  
21  
22

23 As of 17 May 2020, a total of 356,515 tests were performed in the Czech  
24 Republic, and the diagnosis of COVID-19 was confirmed in 8,475 cases. Of the  
25 confirmed COVID-19 cases, 464 patients with unknown history in the National  
26 Health Information System (NHIS) or the patients being foreign nationals with  
27 unknown medical history – were excluded from the analysis, and further 556  
28 patients with a follow-up period shorter than 14 days (i. e. patients diagnosed  
29 after 3 May 2020) were excluded as well. 90% of events occur within 14 days  
30 (Figure S1). Analysis without censoring and with a fixed follow-up length was  
31 chosen with the objective to simplify visualisation and interpretation of results  
32 of the analysis for its practical application. The basic characteristics of patients  
33 (age, gender) were provided for all patients, data on comorbidities were  
34 available for all patients with match between ISID and NHIS datasets; patients  
35 without match between datasets were earlier excluded from the analysis, no  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 other missing data handling was necessary. On top of that, characteristics of  
4  
5  
6 the cohort diagnosed with COVID-19 were compared to those of the population  
7  
8  
9 of the Czech Republic (10.6 million).

### 10 11 **Diagnosis**

12  
13  
14 The diagnosis of COVID-19 was based on the detection of SARS-CoV-2 by  
15  
16  
17 real-time reverse transcription polymerase chain reaction (RT-PCR). At first, the  
18  
19  
20 analyses were performed in the National Reference Laboratory of the National  
21  
22  
23 Institute of Public Health (NIPH); other certified laboratories were later  
24  
25  
26 appointed to carry out RT-PCR testing as well.

### 27 28 29 **Systematic collection of data**

30  
31  
32 The analysis was done on data from the National Health Information  
33  
34  
35 System (NHIS), which was supplemented with data from the Information  
36  
37  
38 System of Infectious Diseases (ISID). Data in the ISID are collected in  
39  
40  
41 compliance with Act No. 258/2000 Coll. on Protection of Public Health,  
42  
43  
44 whereas data in the NHIS are collected – and interconnected with data from  
45  
46  
47 ISID – in accordance with Act No. 372/2011 Coll., on Health Services and  
48  
49  
50 Conditions of Their Provision. Due to this legal mandate, the retrospective  
51  
52  
53 analyses did not require either approval by an ethics committee or informed  
54  
55  
56 consents from participants; moreover, it is a population-based analysis of all  
57  
58  
59 diagnosed COVID-19 cases in the Czech Republic. The cohort covers also  
60

1  
2  
3 asymptomatic and oligosymptomatic patients identified thanks to  
4  
5  
6 epidemiological monitoring.  
7

8  
9 The latest data on COVID-19 patients, the severity of their condition as well as  
10  
11 the necessity of hospitalisation in an ICU, including the use of mechanical  
12  
13 ventilation or ECMO, together with information on death, have been entered  
14  
15 into the ISID in real time. Apart from that, data on COVID-19 patients have  
16  
17 been enriched with information on their comorbidities: this information is  
18  
19 available in the National Register of Reimbursed Health Services (NRRHS),  
20  
21 which contains data on all healthcare reported within the public health  
22  
23 insurance system (accounting for almost 100% of healthcare provided in the  
24  
25 Czech Republic). Comorbidities are determined from combinations of reported  
26  
27 diagnoses (ICD-10), ATC codes of drugs, and procedures defined in code lists  
28  
29 used by Czech health insurance companies. Only diseases and conditions with a  
30  
31 higher prevalence in the population or those identified in literature[7,9,15–17]  
32  
33 as potential predictors of a severe course of COVID-19 were evaluated, with the  
34  
35 aim to assess their potential influence on the resulting model.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

### 48 ***Statistical analysis***

49  
50  
51 Standard descriptive statistics were used to describe the data:  
52  
53 categorical variables were described by absolute and relative frequencies,  
54  
55  
56  
57 whereas continuous variables were described by means and standard  
58  
59  
60

1  
2  
3 deviations. The Fisher's exact test (for categorical variables) and Mann–  
4  
5  
6 Whitney U test (for continuous variables) were used to compare characteristics  
7  
8  
9 between groups depending on the monitored endpoint, unless stated  
10  
11  
12 otherwise. The predictive power of patient characteristics with regard to the  
13  
14  
15 analysed endpoint was evaluated by univariable and multivariable logistic  
16  
17  
18 regression and described by odds ratios, their 95% confidence intervals and  
19  
20  
21 statistical significance; a backward stepwise algorithm was used to choose the  
22  
23  
24 optimal model, and a ROC analysis was employed to evaluate the overall  
25  
26  
27 predictive power of the model. A flexible calibration curve [18] was adopted for  
28  
29  
30 the evaluation of goodness of fit of the model. The results of the model were  
31  
32  
33 expressed by a risk heat map taking account of the patients' age, sex and  
34  
35  
36 comorbidities. A 10-fold cross-validation was performed to obtain estimates of  
37  
38  
39 model performance that are adjusted for in-sample optimism. A model was  
40  
41  
42 created in accordance with TRIPOD check list for prediction model  
43  
44  
45 development and validation [19]. The analysis was computed using the Vertica  
46  
47  
48 database and a MS SQL Server for data pre-processing and SPSS 25.0.0.1 and R-  
49  
50  
51 3.6.1 for the statistical analysis of data. The level of statistical significance was  
52  
53  
54 set at  $\alpha=0.05$  for all analyses.  
55  
56  
57  
58  
59  
60



## Results

Of the total of 7,455 evaluated patients, 1,182 (15.9%) were hospitalised, 465 of them (6.2%) developed a severe course of the disease (i.e. reached the primary endpoint – death or the necessity of intensive care being provided in the Intensive care units (ICU), that include mechanical ventilation and/or ECMO support): 174 patients (2.3%) required mechanical ventilation, 11 patients (0.1%) were provided ECMO, and 287 patients (3.8%) died. Patients with the monitored endpoint were older ( $74.8 \pm 13.4$  vs  $45.4 \pm 20.2$  years), more frequently of male sex and suffered at least one of all monitored comorbidities (Table 1,  $p < 0.001$  for all parameters; for univariable logistic regression results, see Table S1). Older age was determined by the multivariable logistic regression analysis to be the most significant predictor: the risk of a severe course of the disease increases progressively from the age of 40 years onwards (Table 2). Male sex, chronic kidney disease, chronic obstructive pulmonary disease, recent history of cancer (in the last five years), chronic heart failure, acid related disorders treated with proton-pump inhibitors and diabetes mellitus were other significant predictors; the latter six conditions are hereinafter referred to as **prognostically significant comorbidities** (Table 2). The overall predictive power of the model, evaluated by the ROC analysis and expressed by the AUC, was 0.893 (95% CI: 0.880–0.907; sensitivity 85.8% and

1  
2  
3 specificity 80.3%). After performing the 10-fold cross-validation to validate the  
4  
5  
6 results, the average AUC of 0.891 (in the range 0.856–0.943) was obtained. For  
7  
8  
9 the purpose of an easier interpretation in clinical practice, a simplified version  
10  
11  
12 of the model was developed, taking into consideration the number of  
13  
14  
15 prognostically significant comorbidities obtained from the previous model  
16  
17  
18 (Table 3). Both original and simplified models are well-calibrated, as is  
19  
20  
21 supported by calibration curves in the Supplementary Figures (Figure S2A for  
22  
23  
24 the original model and Figure S2B for the simplified model). The results of the  
25  
26  
27 simplified model were visualised by risk heat maps for men and women  
28  
29  
30 separately (Figure 1), and we called this diagram a “**covidogram**”. The diagram  
31  
32  
33 shows how the risk increases progressively with age and with the number of  
34  
35  
36 prognostically significant comorbidities.

37  
38 It is obvious from the comparison of basic patient characteristics (Table 1) and  
39  
40  
41 the results of the multivariable analysis (Table 2) that although a number of  
42  
43  
44 conditions occur more frequently in the group of patients with a severe course  
45  
46  
47 of the disease, not all of them are independent predictors (coronary artery  
48  
49  
50 disease, history of stroke, atrial fibrillation, hypertension or treatment by ACEIs  
51  
52  
53 and ARBs).

54  
55 The comparison of characteristics of patients with confirmed COVID-19  
56  
57  
58 to those of the entire population of the Czech Republic showed that COVID-19  
59  
60

1  
2  
3 patients are slightly older and have the monitored comorbidities slightly more  
4  
5 frequently. (Table S2).  
6  
7  
8  
9

## 10 11 **Discussion**

### 12 13 ***New findings about COVID-19***

14  
15 We have developed a prognostic model for the prediction of the severe  
16  
17 course of COVID-19 in consecutive patients with positive COVID-19 RT-PCR test.  
18  
19 This a simple tool called “covidogram” has a very good predictive power (AUC  
20  
21 0.893). Age is the most significant factor, and the risk increases progressively  
22  
23 from the age of 40 years onwards. To our knowledge, this is the first study to  
24  
25 suggest that acid related disorders treated by proton pump inhibitors might be  
26  
27 independent risk predictors as well. By contrast, not all cardiovascular diseases  
28  
29 (such as uncomplicated hypertension or coronary artery disease) increase the  
30  
31 risk of a severe course of COVID-19.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

43 The “covidogram” was designed as a model to assess the risk of  
44  
45 unfavourable development of the patient’s condition based on his/her history  
46  
47 of chronic disease, and can serve as a tool to estimate the number of severe  
48  
49 cases of COVID-19 in a population. When assessing the risk for an individual  
50  
51 patient in clinical practice, it is certainly necessary to take into consideration  
52  
53 also other pieces of information on the current condition of that patient  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 (respiratory rate, peripheral oxygen saturation, level of consciousness, urea  
4  
5  
6 level, C reactive protein[20], procalcitonin, aspartate aminotransferase[17],  
7  
8  
9 high temperature[16], elevation of cardiac markers, lung infiltrates >50%[9]) as  
10  
11  
12 well as obesity, which can also increase the risk of a severe course of COVID-19  
13  
14  
15 [21].

### 16 17 ***Acid-related disorders***

18  
19  
20 Surprisingly, our analysis revealed that the presence of acid-related  
21  
22  
23 disorders might be theoretically linked to a severe course of COVID-19. Patients  
24  
25  
26 were predominantly treated with proton-pump inhibitors (1,175 patients in  
27  
28  
29 total, out of which 706 were treated with omeprazole and 402 with  
30  
31  
32 pantoprazole as the two most frequently used drugs); only a small proportion  
33  
34  
35 of them were treated with H<sub>2</sub>-receptor antagonists (30 patients). The main  
36  
37  
38 indications for treatment with these drugs generally involve gastro-  
39  
40  
41 oesophageal reflux disease, functional dyspepsia, gastric and duodenal ulcers,  
42  
43  
44 gastric acid hypersecretory states as well as gastroprotection in patients using  
45  
46  
47 non-steroidal anti-inflammatory drugs, dual antiplatelet therapy,  
48  
49  
50 biphosphonates or some selective serotonin reuptake inhibitors (SSRIs). The  
51  
52  
53 effect of inhibition of hydrochloric acid secretion is followed by an increase in  
54  
55  
56 the intragastric pH (to a value above 2–4), which might hypothetically decrease  
57  
58  
59 the physiological bactericidal/virucidal effect of gastric acid and decrease the  
60

1  
2  
3 activity of lysosomal enzymes. Published data showed that long-term use of  
4  
5  
6 proton-pump inhibitors could slightly increase the risk of pneumonia[22,23]  
7  
8  
9 and enteric infections[24].

10  
11 Our comparison of patients with and without acid-related disorders (Table S3)  
12  
13  
14 showed that patients with these disorders are markedly older and have  
15  
16  
17 prognostically significant comorbidities more frequently. Our analysis cannot  
18  
19  
20 determine whether there is any causal relationship between the presence of  
21  
22  
23 acid-related disorders and a severe course of COVID-19 or whether it is just a  
24  
25  
26 coincidence. At the same time, it must be stressed out that the vast majority of  
27  
28  
29 patients were treated with proton-pump inhibitors, not with H<sub>2</sub>-receptor  
30  
31  
32 agonists. The observation is complicated also by the fact that some patients  
33  
34  
35 may not be adherent to their PPI regimen and there was great variability in the  
36  
37  
38 amount of time that they have been on PPIs (from one to twelfth month within  
39  
40  
41 2019). Based on our analysis we are not able to decide whether severity of  
42  
43  
44 disease might be theoretically explained by pharmacology or by underlying  
45  
46  
47 pathology of acid related disorders. Recently, Almario et al. demonstrated  
48  
49  
50 association between using proton pump inhibitors and odds of a positive  
51  
52  
53 COVID-19 test [25]. Similar trend was reported by Tarlow [26].

#### 54 **Strengths and limitations**

55  
56  
57  
58  
59  
60

1  
2  
3 This study is based on a fully integrated national health information  
4  
5  
6 system covering the entire population of a country – which proposed a  
7  
8  
9 prediction model estimating individually-based risk of a severe course of  
10  
11  
12 COVID-19. Because this model uses data readily available in health and  
13  
14  
15 administrative registries, it can be easily used for the prediction of intensive  
16  
17  
18 care use in the context of decision-making at the national level.

19  
20 On the other hand, our analysis has a number of limitations. Results of  
21  
22  
23 laboratory, clinical and X-ray examinations performed at the time of patient  
24  
25  
26 admission to hospitals were not available, and these very important pieces of  
27  
28  
29 information could therefore not be analysed; instead, our analysis is based on  
30  
31  
32 administrative data, with the exception of endpoints. Furthermore, analytical  
33  
34  
35 processing of a cohort of patients cannot capture the risk of less frequent  
36  
37  
38 conditions that might increase the risk of a severe course of COVID-19 (e.g.  
39  
40  
41 patients with immunodeficiencies, those after organ transplantation, or those  
42  
43  
44 undergoing immunosuppressive therapy or biological therapy). The cohort  
45  
46  
47 does not include strictly all COVID-19 cases in the Czech Republic because some  
48  
49  
50 patients are asymptomatic and have not been tested. Older peoples with more  
51  
52  
53 comorbidities are probably more likely to have a symptomatic course of COVID-  
54  
55  
56 19. It could be also a reason why the population of patients diagnosed with  
57  
58  
59 COVID-19 is older and with more comorbidities in comparison with the Czech  
60

1  
2  
3 Republic population (Table S2). Due to the retrospective nature of this study,  
4  
5  
6 which is based on data of administrative registries and is focused on the  
7  
8  
9 development of a prediction model, any conclusions regarding the influence of  
10  
11  
12 comorbidities and the consumption of medicinal products should be  
13  
14  
15 interpreted with caution and will require further validation. The in sample  
16  
17  
18 calibration of the model was assessed by a by flexible calibration curves which  
19  
20  
21 confirmed that the predictive model is well calibrated. Out-of-sample  
22  
23  
24 calibration is currently not available as data of large sample of patients from  
25  
26  
27 the second wave COVID-19 in the Czech Republic are still under preparation.  
28  
29  
30

### 31 **Conclusion**

32  
33  
34 The proposed prediction model “covidogram” is based on elementary  
35  
36  
37 independent variables (age, male sex and the presence of chronic disease) and  
38  
39  
40 represents a simple tool that makes it possible to identify – with a high  
41  
42  
43 reliability (AUC 0.893) – patients who are at risk of a severe course of COVID-  
44  
45  
46 19.  
47

48  
49 Finally, the analysis has shown, for the first time, that acid-related disorders  
50  
51  
52 treated with proton-pump inhibitors might also be theoretically associated with  
53  
54  
55 a severe course of the disease.  
56  
57  
58  
59  
60

1  
2  
3 **A competing interests statement** All authors have disclosed that they do not  
4  
5  
6 have any conflicts of interest (no support from any organisation for the  
7  
8  
9 submitted work; no financial relationships with any organisations that might  
10  
11  
12 have an interest in the submitted work; no other relationships or activities that  
13  
14  
15 could appear to have influenced the submitted work).

## 20 **References**

- 21  
22  
23  
24  
25  
26 1 Hoffmann M, Kleine-Weber H, Schroeder S, *et al.* SARS-CoV-2 Cell Entry  
27  
28 Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven  
29  
30 Protease Inhibitor. *Cell* 2020;**181**:271-280.e8.  
31  
32 doi:10.1016/j.cell.2020.02.052  
33  
34  
35  
36  
37 2 Sutton D, Fuchs K, D'Alton M, *et al.* Universal Screening for SARS-CoV-2 in  
38  
39 Women Admitted for Delivery. *N Engl J Med* Published Online First: 13 April  
40  
41 2020. doi:10.1056/NEJMc2009316  
42  
43  
44  
45  
46 3 Aghagoli G, Gallo Marin B, Katchur NJ, *et al.* Neurological Involvement in  
47  
48 COVID-19 and Potential Mechanisms: A Review. *Neurocrit Care* 2020;:1–10.  
49  
50  
51 doi:10.1007/s12028-020-01049-4  
52  
53  
54  
55  
56  
57  
58  
59  
60



- 1  
2  
3  
4 4 Aghagoli G, Gallo Marin B, Soliman LB, *et al.* Cardiac involvement in  
5  
6 COVID-19 patients: Risk factors, predictors, and complications: A review. *J*  
7  
8 *Card Surg* Published Online First: 19 April 2020. doi:10.1111/jocs.14538  
9  
10  
11  
12 5 Giacomelli A, Pezzati L, Conti F, *et al.* Self-reported olfactory and taste  
13  
14 disorders in SARS-CoV-2 patients: a cross-sectional study. *Clin Infect Dis Off*  
15  
16 *Publ Infect Dis Soc Am* Published Online First: 26 March 2020.  
17  
18 doi:10.1093/cid/ciaa330  
19  
20  
21  
22  
23 6 Han C, Duan C, Zhang S, *et al.* Digestive Symptoms in COVID-19 Patients  
24  
25 With Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing,  
26  
27 and Outcomes. *Am J Gastroenterol* Published Online First: 15 April 2020.  
28  
29 doi:10.14309/ajg.0000000000000664  
30  
31  
32  
33  
34 7 Huang C, Wang Y, Li X, *et al.* Clinical features of patients infected with 2019  
35  
36 novel coronavirus in Wuhan, China. *Lancet Lond Engl* 2020;**395**:497–506.  
37  
38 doi:10.1016/S0140-6736(20)30183-5  
39  
40  
41  
42  
43 8 Kim I-C, Kim JY, Kim HA, *et al.* COVID-19-related myocarditis in a 21-year-old  
44  
45 female patient. *Eur Heart J* Published Online First: 13 April 2020.  
46  
47 doi:10.1093/eurheartj/ehaa288  
48  
49  
50  
51 9 Wang D, Hu B, Hu C, *et al.* Clinical Characteristics of 138 Hospitalized  
52  
53 Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan,  
54  
55 China. *JAMA* 2020;**323**:1061–9. doi:10.1001/jama.2020.1585  
56  
57  
58  
59  
60

- 1  
2  
3 10 WHO. Coronavirus disease (COVID-19) pandemic. Available from  
4  
5  
6 <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>.  
7  
8  
9 Accessed 12 Dec 2020.  
10  
11 11 Gandhi RT, Lynch JB, Rio C del. Mild or Moderate Covid-19. *N Engl J Med*  
12  
13  
14 Published Online First: 24 April 2020. doi:10.1056/NEJMcp2009249  
15  
16  
17 12 Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. *N Engl J Med*  
18  
19  
20 2020;**0**:null. doi:10.1056/NEJMcp2009575  
21  
22  
23 13 Mehra MR, Desai SS, Kuy S, *et al*. Cardiovascular Disease, Drug Therapy, and  
24  
25  
26 Mortality in Covid-19. *N Engl J Med* Published Online First: 1 May 2020.  
27  
28  
29 doi:10.1056/NEJMoa2007621  
30  
31  
32 14 Wang T, Tang C, Chen R, *et al*. Clinical Features of Coronavirus Disease 2019  
33  
34  
35 Patients With Mechanical Ventilation: A Nationwide Study in China. *Crit*  
36  
37  
38 *Care Med* 2020;**Online First**. doi:10.1097/CCM.0000000000004473  
39  
40  
41 15 CDC, Coronavirus-19. Available from  
42  
43  
44 [https://www.cdc.gov/coronavirus/2019-ncov/need-extra-](https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html)  
45  
46  
47 [precautions/people-with-medical-conditions.html](https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html).  
48  
49  
50 16 Wu C, Chen X, Cai Y, *et al*. Risk Factors Associated With Acute Respiratory  
51  
52  
53 Distress Syndrome and Death in Patients With Coronavirus Disease 2019  
54  
55  
56 Pneumonia in Wuhan, China. *JAMA Intern Med* Published Online First: 13  
57  
58  
59 March 2020. doi:10.1001/jamainternmed.2020.0994  
60

- 1  
2  
3 17 Chen R, Liang W, Jiang M, *et al.* Risk Factors of Fatal Outcome in  
4  
5  
6 Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide  
7  
8  
9 Analysis in China. *Chest* Published Online First: 15 April 2020.  
10  
11  
12 doi:10.1016/j.chest.2020.04.010  
13
- 14 18 Van Calster B, Nieboer D, Vergouwe Y, *et al.* A calibration hierarchy for risk  
15  
16  
17 models was defined: from utopia to empirical data. *J Clin Epidemiol*  
18  
19  
20 2016;**74**:167–76. doi:10.1016/j.jclinepi.2015.12.005  
21  
22
- 23 19 Collins Gary S., Reitsma Johannes B., Altman Douglas G., *et al.* Transparent  
24  
25  
26 Reporting of a Multivariable Prediction Model for Individual Prognosis or  
27  
28  
29 Diagnosis (TRIPOD). *Circulation* 2015;**131**:211–9.  
30  
31  
32 doi:10.1161/CIRCULATIONAHA.114.014508  
33
- 34 20 Knight SR, Ho A, Pius R, *et al.* Risk stratification of patients admitted to  
35  
36  
37 hospital with covid-19 using the ISARIC WHO Clinical Characterisation  
38  
39  
40 Protocol: development and validation of the 4C Mortality Score. *BMJ*  
41  
42  
43 2020;**370**. doi:10.1136/bmj.m3339  
44  
45
- 46 21 Malik P, Patel U, Patel K, *et al.* Obesity a predictor of outcomes of COVID-19  
47  
48  
49 hospitalized patients- A systematic Review and Meta-Analysis. *J Med Virol*  
50  
51  
52 Published Online First: 25 September 2020. doi:10.1002/jmv.26555  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 22 Eom C-S, Jeon CY, Lim J-W, *et al.* Use of acid-suppressive drugs and risk of  
4  
5 pneumonia: a systematic review and meta-analysis. *CMAJ Can Med Assoc J J*  
6  
7  
8  
9 *Assoc Medicale Can* 2011;**183**:310–9. doi:10.1503/cmaj.092129  
10  
11  
12 23 Zirk-Sadowski J, Masoli JA, Delgado J, *et al.* Proton-Pump Inhibitors and  
13  
14 Long-Term Risk of Community-Acquired Pneumonia in Older Adults. *J Am*  
15  
16 *Geriatr Soc* 2018;**66**:1332–8. doi:10.1111/jgs.15385  
17  
18  
19  
20 24 Moayyedi P, Eikelboom JW, Bosch J, *et al.* Safety of Proton Pump Inhibitors  
21  
22 Based on a Large, Multi-Year, Randomized Trial of Patients Receiving  
23  
24 Rivaroxaban or Aspirin. *Gastroenterology* 2019;**157**:682-691.e2.  
25  
26  
27  
28  
29  
30  
31  
32 25 Almario CV, Chey WD, Spiegel BMR. Increased Risk of COVID-19 Among  
33  
34 Users of Proton Pump Inhibitors. *Am J Gastroenterol* Published Online First:  
35  
36  
37  
38 25 August 2020. doi:10.14309/ajg.0000000000000798  
39  
40  
41 26 Tarlow B, Gubatan J, Khan MA, *et al.* Are Proton Pump Inhibitors  
42  
43 Contributing to SARS-COV-2 Infection? *Off J Am Coll Gastroenterol ACG*  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Figure legend**  
4

5  
6 Figure 1. COVIDOGRAM – predicted probability of severe course of Covid-19 for  
7  
8 men and women – visualization of simplified multivariable logistic regression  
9  
10  
11 model (for more details, see Table 3)  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

**Table 1.** Characteristics of COVID-19 patients according to endpoint

	<b>With severe course</b> <b>N = 465</b>	<b>Without severe course</b> <b>N = 6,990</b>
<b>Basic characteristics</b>		
Men	260 (55.9%)	3,221 (46.1%)
Age, mean $\pm$ SD	74.8 $\pm$ 13.4	45.4 $\pm$ 20.2
<b>History</b>		
Hypertension	258 (55.5%)	1,266 (18.1%)
Atrial fibrillation	75 (16.1%)	179 (2.6%)
History of stroke	55 (11.8%)	131 (1.9%)
History of MI or PCI	32 (6.9%)	106 (1.5%)
Chronic heart failure	90 (19.4%)	157 (2.2%)
Chronic kidney disease	99 (21.3%)	215 (3.1%)
Diabetes mellitus	127 (27.3%)	519 (7.4%)
Chronic obstructive pulmonary disease	102 (21.9%)	643 (9.2%)
Acid-related disorders	206 (44.3%)	999 (14.3%)
Recent history of cancer ( $\leq$ 5 years)	48 (10.3%)	169 (2.4%)
Rheumatoid arthritis	14 (3.0%)	75 (1.1%)
<b>Treatment</b>		
ACE inhibitors	182 (39.1%)	947 (13.5%)
ARBs	85 (18.3%)	543 (7.8%)
Calcium channel blockers	121 (26.0%)	584 (8.4%)
Beta-blockers	212 (45.6%)	884 (12.6%)
Diuretics	214 (46.0%)	814 (11.6%)
Anticoagulants / antithrombotic agents	143 (30.8%)	502 (7.2%)
Statins	169 (36.3%)	882 (12.6%)

ACE = angiotensin-converting enzyme, ARBs = angiotensin II receptor blockers, MI = myocardial infarction, PCI = percutaneous coronary intervention

**Table 2.** Multivariable logistic regression model using backward stepwise algorithm for selection of independent predictors of severe course of COVID-19. Age, sex and comorbidities from Table 1 were entered into the model.

Predictors	Regression coefficients	SE	OR (95% CI)	P-value
<b>Sex</b>				
Women			Reference category	
Men	0.742	0.112	2.10 (1.68; 2.62)	< 0.001
<b>Age</b>				
< 40 years			Reference category	
40–49 years	1.227	0.464	3.41 (1.37; 8.48)	<b>0.008</b>
50–59 years	2.478	0.414	11.92 (5.30; 26.81)	< 0.001
60–69 years	3.424	0.399	30.68 (14.04; 67.04)	< 0.001
70–79 years	4.109	0.398	60.89 (27.93; 132.73)	< 0.001
80–89 years	4.725	0.400	112.68 (51.48; 246.63)	< 0.001
90+ years	5.299	0.428	200.12 (86.50; 462.97)	< 0.001
<b>Comorbidities</b>				
Chronic kidney disease	0.679	0.157	1.97 (1.45; 2.68)	< 0.001
Chronic obstructive pulmonary disease	0.436	0.144	1.55 (1.17; 2.05)	<b>0.002</b>
Recent history of cancer ( $\leq 5$ years)	0.432	0.194	1.54 (1.05; 2.25)	<b>0.026</b>
Chronic heart failure	0.408	0.166	1.50 (1.09; 2.08)	<b>0.014</b>
Acid-related disorders	0.382	0.118	1.47 (1.16; 1.85)	<b>0.001</b>
Diabetes mellitus	0.323	0.129	1.38 (1.07; 1.78)	<b>0.012</b>
<b>Intercept</b>	-6.448	0.386	-	< 0.001

Overall predictive power: AUC (95% CI): 0.893 (0.880; 0.907); sensitivity 85.8% and specificity 80.3%.

**Table 3.** Simplified multivariable logistic regression model based on predictors selected by a backward stepwise algorithm


Predictors	Regression coefficients	SE	OR (95% CI)	P-value
<b>Sex</b>				
Women			Reference category	
Men	0.744	0.112	2.10 (1.69; 2.62)	< 0.001
<b>Age</b>				
< 40 years			Reference category	
40–49 years	1.215	0.464	3.37 (1.36; 8.37)	0.009
50–59 years	2.459	0.414	11.69 (5.20; 26.30)	< 0.001
60–69 years	3.388	0.398	29.59 (13.56; 64.59)	< 0.001
70–79 years	4.082	0.397	59.27 (27.22; 129.05)	< 0.001
80–89 years	4.700	0.399	109.93 (50.31; 240.20)	< 0.001
90+ years	5.302	0.427	200.66 (86.84; 463.63)	< 0.001
<b>Morbidity level*</b>				
1-point increase	0.448	0.049	1.56 (1.42; 1.72)	< 0.001
<b>Intercept</b>	-6.453	0.386		< 0.001

Overall predictive power: AUC (95% CI): 0.893 (0.879; 0.907); sensitivity 85.8% and specificity 80.3%.

\*One point for each comorbidity: chronic kidney disease, chronic obstructive pulmonary disease, recent history of cancer ( $\leq 5$  years), chronic heart failure, acid-related disorders, diabetes mellitus (maximum of 4 points per person, additional points were not considered due to a low prevalence in our cohort).



Figure 1.



**Table S1.** Univariable logistic regression models

	Regression coefficients	SE	OR (95% CI)	P-value
<b>Basic characteristics</b>				
Sex – men (ref. women)	0.395	0.096	1.48 (1.23; 1.79)	< 0.001
Age 40–49 years (ref. < 40 years)	1.260	0.464	3.52 (1.42; 8.75)	0.007
Age 50–59 years (ref. < 40 years)	2.553	0.413	12.84 (5.72; 28.85)	< 0.001
Age 60–69 years (ref. < 40 years)	3.716	0.396	41.09 (18.93; 89.20)	< 0.001
Age 70–79 years (ref. < 40 years)	4.584	0.391	97.92 (45.52; 210.66)	< 0.001
Age 80–89 years (ref. < 40 years)	5.096	0.392	163.44 (75.80; 352.40)	< 0.001
Age 90+ years (ref. < 40 years)	5.555	0.418	258.59 (113.92; 586.98)	< 0.001
<b>History</b>				
Hypertension	1.729	0.098	5.64 (4.65; 6.83)	< 0.001
Atrial fibrillation	1.990	0.147	7.32 (5.48; 9.76)	< 0.001
History of stroke	1.949	0.169	7.02 (5.05; 9.77)	< 0.001
History of MI or PCI	1.569	0.208	4.80 (3.19; 7.21)	< 0.001
Chronic heart failure	2.346	0.142	10.45 (7.90; 13.81)	< 0.001
Chronic kidney disease	2.143	0.133	8.52 (6.57; 11.06)	< 0.001
Diabetes mellitus	1.544	0.114	4.68 (3.75; 5.85)	< 0.001
Chronic obstructive pulmonary disease	1.020	0.119	2.77 (2.19; 3.51)	< 0.001
Acid-related disorders	1.562	0.099	4.77 (3.93; 5.80)	< 0.001
Recent history of cancer ( $\leq$ 5 years)	1.536	0.171	4.65 (3.32; 6.50)	< 0.001
Rheumatoid arthritis	1.052	0.295	2.86 (1.60; 5.10)	< 0.001
<b>Treatment</b>				
ACE inhibitors	1.412	0.101	4.10 (3.37; 5.00)	< 0.001
ARBs	0.977	0.128	2.66 (2.07; 3.41)	< 0.001
Calcium channel blockers	1.350	0.114	3.86 (3.08; 4.83)	< 0.001
Beta-blockers	1.756	0.100	5.79 (4.76; 7.04)	< 0.001
Diuretics	1.867	0.100	6.47 (5.31; 7.87)	< 0.001
Anticoagulants / antithrombotic agents	1.747	0.111	5.74 (4.62; 7.13)	< 0.001
Statins	1.375	0.103	3.95 (3.23; 4.84)	< 0.001

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

**Table S2.** Characteristics of COVID-19 patients in comparison to general population of the Czech Republic

	COVID-19 patients N = 7,455	General population N = 10.6 million	P-value
<b>Basic characteristics</b>			
Men	46.7%	49.1%	< 0.001
Age, mean $\pm$ SD	47.2 $\pm$ 21.1	42.5 $\pm$ 23.1	< 0.001
<b>Medical history</b>			
Hypertension	20.4%	17.5%	< 0.001
Atrial fibrillation	3.4%	2.3%	< 0.001
History of stroke	2.5%	1.4%	< 0.001
History of MI or PCI	1.9%	1.5%	0.011
Chronic heart failure	3.3%	1.6%	< 0.001
Chronic kidney disease	4.2%	2.4%	< 0.001
Diabetes mellitus	8.7%	7.2%	< 0.001
Chronic obstructive pulmonary disease	10.0%	8.4%	< 0.001
Acid-related disorders	16.2%	11.7%	< 0.001
Recent history of cancer ( $\leq$ 5 years)	2.9%	2.1%	< 0.001
Rheumatoid arthritis	1.2%	0.9%	0.003
<b>Treatment</b>			
ACE inhibitors	15.1%	14.5%	0.100
ARBs	8.4%	7.6%	0.009
Calcium channel blockers	9.5%	8.8%	0.066
Beta-blockers	14.7%	12.0%	< 0.001
Diuretics	13.8%	11.6%	< 0.001
Anticoagulants / antithrombotic agents	8.7%	6.1%	< 0.001
Statins	14.1%	13.9%	0.701

P-value of binomial test (categorical variables) and P-value of one-sample t-test (continuous variables).  
 ACE = angiotensin converting enzyme, ARB = angiotensin II receptor blockers, MI = myocardial infarction,  
 PCI = percutaneous coronary intervention


**Table S3.** Characteristics of COVID-19 patients by using drugs for acid-related disorders

	Using drugs N = 1,205	Not using drugs N = 6,250	P-value
<b>Basic characteristics</b>			
Men	524 (43.5%)	2 957 (47.3%)	<b>0.015</b>
Age, mean $\pm$ SD	62.6 $\pm$ 18.3	44.2 $\pm$ 20.2	<b>&lt; 0.001</b>
<b>Medical history</b>			
Hypertension	542 (45.0%)	982 (15.7%)	<b>&lt; 0.001</b>
Atrial fibrillation	125 (10.4%)	129 (2.1%)	<b>&lt; 0.001</b>
History of stroke	91 (7.6%)	95 (1.5%)	<b>&lt; 0.001</b>
History of MI or PCI	69 (5.7%)	69 (1.1%)	<b>&lt; 0.001</b>
Chronic heart failure	138 (11.5%)	109 (1.7%)	<b>&lt; 0.001</b>
Chronic kidney disease	158 (13.1%)	156 (2.5%)	<b>&lt; 0.001</b>
Diabetes mellitus	222 (18.4%)	424 (6.8%)	<b>&lt; 0.001</b>
Chronic obstructive pulmonary disease	271 (22.5%)	474 (7.6%)	<b>&lt; 0.001</b>
Recent history of cancer ( $\leq$ 5 years)	93 (7.7%)	124 (2.0%)	<b>&lt; 0.001</b>
Rheumatoid arthritis	39 (3.2%)	50 (0.8%)	<b>&lt; 0.001</b>
<b>Treatment</b>			
ACE inhibitors	348 (28.9%)	781 (12.5%)	<b>&lt; 0.001</b>
ARBs	217 (18.0%)	411 (6.6%)	<b>&lt; 0.001</b>
Calcium channel blockers	253 (21.0%)	452 (7.2%)	<b>&lt; 0.001</b>
Beta-blockers	422 (35.0%)	674 (10.8%)	<b>&lt; 0.001</b>
Diuretics	399 (33.1%)	629 (10.1%)	<b>&lt; 0.001</b>
Anticoagulants / antithrombotic agents	270 (22.4%)	375 (6.0%)	<b>&lt; 0.001</b>
Statins	369 (30.6%)	682 (10.9%)	<b>&lt; 0.001</b>


P-value of Fisher's exact test (categorical variables) and P-value of Mann-Whitney U test (continuous variables).

ACE = angiotensin-converting enzyme, ARBs = angiotensin II receptor blockers, MI = myocardial infarction, PCI = percutaneous coronary intervention

**Figure S1.** Time to analysed endpoint (severe condition)



**Figure S2.** Calibration curves of the multivariable logistic regression model (A) and its simplified version (B)



## TRIPOD Checklist: Prediction Model Development and Validation

Section/Topic	Item	Checklist Item	Page	
<b>Title and abstract</b>				
Title	1	D;V	Identify the study as developing and/or validating a multivariable prediction model, the target population, and the outcome to be predicted.	1
Abstract	2	D;V	Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, statistical analysis, results, and conclusions.	5
<b>Introduction</b>				
Background and objectives	3a	D;V	Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models.	8
	3b	D;V	Specify the objectives, including whether the study describes the development or validation of the model or both.	9
<b>Methods</b>				
Source of data	4a	D;V	Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for the development and validation data sets, if applicable.	10
	4b	D;V	Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow-up.	10
Participants	5a	D;V	Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centres.	11
	5b	D;V	Describe eligibility criteria for participants.	10
	5c	D;V	Give details of treatments received, if relevant.	-
Outcome	6a	D;V	Clearly define the outcome that is predicted by the prediction model, including how and when assessed.	14
	6b	D;V	Report any actions to blind assessment of the outcome to be predicted.	-
Predictors	7a	D;V	Clearly define all predictors used in developing or validating the multivariable prediction model, including how and when they were measured.	12
	7b	D;V	Report any actions to blind assessment of predictors for the outcome and other predictors.	-
Sample size	8	D;V	Explain how the study size was arrived at.	10
Missing data	9	D;V	Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method.	10
Statistical analysis methods	10a	D	Describe how predictors were handled in the analyses.	12
	10b	D	Specify type of model, all model-building procedures (including any predictor selection), and method for internal validation.	13
	10c	V	For validation, describe how the predictions were calculated.	13
	10d	D;V	Specify all measures used to assess model performance and, if relevant, to compare multiple models.	13
	10e	V	Describe any model updating (e.g., recalibration) arising from the validation, if done.	-
Risk groups	11	D;V	Provide details on how risk groups were created, if done.	-
Development vs. validation	12	V	For validation, identify any differences from the development data in setting, eligibility criteria, outcome, and predictors.	-
<b>Results</b>				
Participants	13a	D;V	Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful.	10
	13b	D;V	Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome.	T1
	13c	V	For validation, show a comparison with the development data of the distribution of important variables (demographics, predictors and outcome).	-
Model development	14a	D	Specify the number of participants and outcome events in each analysis.	14
	14b	D	If done, report the unadjusted association between each candidate predictor and outcome.	S4
Model specification	15a	D	Present the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point).	T2, S1
	15b	D	Explain how to use the prediction model.	F1
Model performance	16	D;V	Report performance measures (with CIs) for the prediction model.	14
Model-updating	17	V	If done, report the results from any model updating (i.e., model specification, model performance).	-
<b>Discussion</b>				
Limitations	18	D;V	Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data).	19
Interpretation	19a	V	For validation, discuss the results with reference to performance in the development data, and any other validation data.	-
	19b	D;V	Give an overall interpretation of the results, considering objectives, limitations, results from similar studies, and other relevant evidence.	19
Implications	20	D;V	Discuss the potential clinical use of the model and implications for future research.	20
<b>Other information</b>				
Supplementary information	21	D;V	Provide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets.	3
Funding	22	D;V	Give the source of funding and the role of the funders for the present study.	2

\*Items relevant only to the development of a prediction model are denoted by D, items relating solely to a validation of a prediction model are denoted by V, and items relating to both are denoted D;V. We recommend using the TRIPOD Checklist in conjunction with the TRIPOD Explanation and Elaboration document.